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Mosaicism and the genetic architecture of congenital heart disease 
Alexander Hsieh 
 
Congenital heart disease (CHD) is characterized by structural defects of the heart and 
great vessels.  It is the most common birth defect, affecting an estimated 1% of live births, and is 
the leading cause of mortality among birth defects.  Despite recent progress in genetic research, 
more than 50% of CHD cases remain unexplained.  An estimated 23% are due to aneuploidies 
and copy number variants and up to 30% has been attributed to de novo variation, though that 
number ranges between 3-30% depending on CHD complexity.   
The contribution of somatic mosaicism, or de novo genetic mutations arising after oocyte 
fertilization, to congenital heart disease (CHD) is not well understood due to limitations in 
sample size, detection method, and validation rate. Further, the relationship between mosaicism 
in blood and cardiovascular tissue has not been determined. We developed a computational 
method, Expectation-Maximization-based detection of Mosaicism (EM-mosaic), to analyze 
mosaicism in exome sequences of 2530 CHD proband-parent trios. EM-mosaic accurately 
detected 309 mosaic mutations in blood, with 85 of 94 (90%) candidates tested independently 
confirmed.  We found twenty-five likely damaging mosaics in plausible CHD-risk genes, 
affecting 1% of our cohort. Variants in these genes predicted as damaging had higher variant 
  
allele fraction than benign variants, suggesting a role in CHD. The frequency of protein-coding 
mosaic variants detectable in blood was 0.122 or roughly 1 in 8 individuals. Analysis of 66 
individuals with matched cardiac tissue available revealed both tissue-specific and shared 
mosaicism, with shared mosaics generally having higher allele fraction.  
CHD patients often present with comorbid cardiac and extracardiac anomalies that 
further their impact quality of life.  Neurodevelopmental disorders (NDDs) are especially 
prevalent in CHD cases compared to the general population, yet the underlying genetic causes 
remain poorly explained. Further, patients with single ventricle defects undergoing surgery often 
later develop arrhythmias and experience worsening ventricular function.  We used a statistical 
approach to dissect the association between de novo variation and these clinical outcomes and 
found that pleiotropic mutations contribute a large fraction of the risk of acquiring NDD and 
abnormal ventricular function phenotypes in CHD patients. We developed a proof-of-concept 
rare variant risk score that combines information from de novo, rare transmitted, and copy-
number variants and show that prediction of outcomes such as NDD can be improved, especially 
in complex CHD cases. 
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Introduction   
0.1 Introduction to congenital heart disease 
Congenital heart disease (CHD) is characterized by structural defects of the heart and 
great vessels.  It is the most common birth defect, affected an estimated 1% of live births, and is 
the leading cause of mortality among birth defects {van der Linde 2011; Yang 2006}.  Incidence 
rate was found to increase between 1977 and 2005 but has since stabilized at 0.8%-1.1%, with 
minor differences attributable to race/ethnicity and methods of diagnosis {Oyen 2009; Bjonard 
2013}. CHD severity is categorized according the complexity of the patient’s anatomical and 
physiological abnormalities and approximately one third of patients have severe manifestations 
requiring surgical intervention shortly after birth {Zaidi 2017}.  Furthermore, CHD patients 
often acquire cardiac and extracardiac abnormalities that impact quality of life, such as 
arrhythmias, myocardial dysfunctions, and neurodevelopmental disorders (NDDs) {Marino 
2012; Calderon 2014; Miller 2005; Burnham 2010}.  While a range of fetal developmental, 
surgical/post-operative, and genetic factors have been found to associate with these abnormalities 
{Marelli 2016}, thus far none have been identified as the primary contributor {Zaidi 2017}.    
Environmental factors that affect risk of cardiovascular defects in the developing fetus 
(during the preconception stage through to the first trimester of pregnancy) have been studied 
extensively and reviews on the topic {Jenkins 2007; Mone 2004} summarizing a large body of 
work have grouped these factors into the following categories: maternal illness, maternal 
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nutrition, and maternal drug exposure.   Maternal illnesses such as phenylketonuria, 
pregestational diabetes, rubella infection, influenza, and other febrile illnesses are most strongly 
associated with CHD, increasing risk by 2-fold in most cases and up to 18-fold for specific 
defects {Jenkins 2007}.   Conditions such as obesity, HIV, systemic lupus erythematosus, and 
epilepsy have also been shown to be associated with CHD, though the quantifiable risk 
difference has yet to be fully understood.  Poor maternal nutrition during pregnancy – 
specifically deficiency or excess of folic acid and retinoic acid (vitamin A) – also directly 
impacts fetal cardiovascular development {Mone 2004} and intake of multivitamin supplements 
have been shown to reduce the risk of CHD in offspring (OR 0.5-0.8) {Jenkins 2007}.  Finally, 
maternal drug exposure has been associated with a 2- to 4-fold increase in risk of CHD {Jenkins 
2007}.  Examples of non-therapeutic drugs include alcohol, cocaine, marijuana, and other 
narcotics {Mone 2004}.  In sum, these non-genetic environmental factors are estimated to 
explain roughly 10% of CHD cases {Zaidi 2017} – comprehensive reviews {Mone 2004; 
Jenkins 2007} are available that offer more detail than the summary presented here.   
Given its impact on reproductive fitness and its sporadic occurrence in families with no 
prior history, CHD is believed to be driven largely by genetic variation, in particular by de novo 
events in more complex CHD presentations.  In terms of etiology, CHD results from disruption 
of key biological pathways involved in normal cardiac development – including but not limited 
to chromatin remodeling {Zaidi 2013; Homsy 2015}, Notch and RAS signaling {Garg 2005; 
Preuss 2016; Gelb 2011; Weismann 2005}, and cilia and sarcomere genes {Li 2015; Kennedy 
2007; Slough 2008}.  Despite progress made by recent large-scale genetic studies, more than 
50% of CHD cases remain unexplained.  There is an established relationship between strength of 
genetic effect (odds ratio) and risk allele frequency {Manolio 2009} and genetic research in 
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CHD, consequently, has largely focused on rare variants with large effect sizes.  Given the 
prevalence and etiology of CHD and our current model that describes many genomic loci each 
contributing weak effects in an additive manner, we are still severely underpowered to detect 
associations between common variation and CHD.  While recent GWAS studies have uncovered 
evidence of potential CHD susceptibility loci {Cordell 2013; Hu 2013; Agopian 2017; Hanchard 
2016}, the impact of common genetic variants has yet to be fully characterized, primarily due to 
sample size limitations. Larger patient cohorts will be necessary to investigate the complete 
spectrum of genetic variation in CHD; this dissertation will focus on rare genetic variation.  In 
terms of rare genetic variation, roughly 1% of CHD cases are attributed to rare inherited 
variation {Schott 1998; Gebbia 1997; Dina 2015; Durst 2015; Garg 2005}, though this number is 
likely an underestimate due to insufficient sample sizes for detecting the smaller genetic effect of 
mutations that are inherited.  An estimated 23% of CHD cases are due to aneuploidies {Hartman 
2011} and copy number variants {Kim 2016} and up to 30% have been attributed to de novo 
variation {Zaidi 2013; Homsy 2015; Sifrim 2016}, though that number ranges between 3% in 
cases with isolated CHD to 30% in cases with complex CHD.  The biological mechanisms 
governing this difference between isolated and complex CHD cases are not yet fully understood 
and we hypothesize that the mutations causing CHD have pleiotropic effects that also contribute 
to poor clinical outcomes in these same individuals. 
 
0.2 Introduction to genetic mosaicism 
Mosaicism is readily observable in nature – certain types of animal coat color variation, 
for example, have been understood to be manifestations of this biological phenomenon for over a 
century.  However, its role in human disease is still an area of active research.  Mosaicism (or 
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post-zygotic mutation) is largely driven by mutational processes of normal aging and 
development, such as errors in DNA replication and repair, retrotransposition, or gain/loss of 
chromosomes of ploidy, among others {De 2011}.  They tend to occur in the early embryonic 
cells of the dividing zygote and result in two or more cell populations with distinct genotypes 
within the same individual {Biesecker 2013}.  The developmental status of the early embryonic 
cell in which the mutation occurs determines the proportion of mutation-carrying cells and tissue 
distribution of these cells in the post-natal child {Acuna-Hidalgo 2015}.   
Clinical manifestation and detection of mosaicism are not yet fully understood; results 
from previous studies suggest that both differ according to the size of the affected region.  Large-
scale chromosomal abnormalities can manifest as mosaic monosomies/trisomies {Hassold 1984; 
Daber 2011} or isochromosome-related disorders {Hook 1983; Raffel 1986} and are typically 
detected via cytogenetic analysis (e.g. cell-by-cell FISH).  Mosaic copy number variants have 
been implicated in developmental disorders {Conlin 2010; King 2015}, aging {Forsberg 2012}, 
hematological malignancies {Jacobs 2012; Laurie 2012}, certain forms of cancer {Lonigro 2011; 
Amarasinghe 2014}, and congenital heart disease {Prabhu 2015} and are conventionally studied 
using array-based comparative genomic hybridization or SNP microarrays.  Mosaic SNVs and 
indels can manifest as cutaneous/dermatological disorders {Happle 1986; Weinstein 1991; Konig 
2000; Hafner 2006; Hafner 2007}, overgrowth disorders {Wiedemann 1983; Lindhurst 2012; 
Poduri 2012; Lee 2012; Riviere 2012; Kurek 2012}, clonal hematopoiesis {Jaiswal 2014; 
Genovese 2014; Xie 2014}, or cancer {Forbes 2008} and were detected in the past using Sanger 
sequencing but more recently have been detected via next-generation sequencing techniques. 
The earliest investigations into mosaicism focused on cutaneous manifestations, as the 
outward manifestation of these phenotypes were more easily recognizable than manifestations in 
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the internal organs {Happle 1993}. Work by Alfred Blaschko in 1901 was among the first 
studies of mosaicism in humans. Invisible under normal conditions, the Lines of Blaschko 
describe the trajectory along which the cutaneous ectoderm and neural crest differentiate from 
the ectoderm and migrate radially from the dorsal neural tube.  These lines become apparent in 
patients with disorders of the melanocytic system whereby mosaic mutations cause 
hyperpigmentation of the skin.  The patterning – e.g. Type 1a “narrow bands” or Type 1b “broad 
bands” – is largely determined by embryological processes such as cell replication, migration, 
and apoptosis, as well as mutation timing and physiological effect {Happle 1993}.  While benign 
in isolation, mosaic hyperpigmentation is often observed alongside more severe clinical features 
in patients with multisystem diseases such as McCune-Albright Syndrome {Happle 1986; 
Weinstein 1991}, CHILD Syndrome {Happle 1990; Konig 2000}, Segmental Neurofibromatosis 
Type 1 {Ruggieri 2011; Maertens 2007; Messiaen 2011}, or Sturge-Weber Syndrome {Shirley 
2013}.   
Overgrowth disorders are another class of phenotypically recognizable conditions with 
readily identifiable affected tissue that lend themselves to the study of mosaicism.  Proteus 
Syndrome {Wiedemann 1983; Lindhurst 2012}, Megencephaly Syndromes {Lee 2012; Poduri 
2012; Riviere 2012}, and CLOVES Syndrome {Kurek 2012} all involve mosaic activating 
mutations in the PIK3C-AKT pathway that result in asymmetric overgrowth of bones, skin, 
organs, or other tissue.  While the studies of the cutaneous disorders described above used lower-
throughput conventional experimental techniques (e.g. denaturing gradient gel electrophoresis 
{Weinstein 1991}, single-strand conformation analysis {Konig 2000}, etc.) available at the time, 
these more recent studies of overgrowth disorders took advantage of higher-throughput next-
generation sequencing (NGS) technology. 
6 
 
In 2012, two large-scale exome-sequencing studies investigating the role of de novo 
variation in neurodevelopmental disorders uncovered pathogenic mosaic mutations in blood, 
prompting further investigation into the disease implications of mosaicism detectable in blood. 
Gilissen et al. and O’Roak et al. sequenced blood samples belonging to large cohorts of 
Intellectual Disability and Autism Spectrum Disorder patients, respectively, and found, in 
addition to pathogenic de novo variants, disease-relevant post-zygotic point mutations that were 
confirmed via Sanger sequencing and ultra-deep resequencing.  In the following years, these 
same research groups and others would go on to publish a set of studies applying various NGS 
techniques to detect mosaicism in the blood of patients with Brain Malformations {Jamuar, 
Walsh 2014}, Intellectual Disability {Acuna-Hidalgo, Gilissen 2015}, Autism Spectrum 
Disorder {Pevsner 2016; Krupp, O’Roak 2017; Lim, Walsh 2017; Dou 2017}, Epilepsy {Stosser 
2018}, Alzheimer’s Disease {Sala Frigerio 2015}, CINCA/NOMID Syndrome {Tanaka 2011}.   
Discrepancies in reported validation rates and fraction of apparent de novo variants 
arising post-zygotically brought to light several key considerations for studying mosaicism: (1) 
sequencing depth and coverage profile affect mosaic detection, (2) extensive filtering is 
necessary to control the false positive rate, and (3) validation should both confirm presence and 
resolve allele fraction.    
There are two key technical challenges when it comes to mosaic detection: distinguishing 
low allele fraction mosaics mutations from technical artifacts and distinguishing high allele 
fraction mosaics from germline heterozygous mutations.  Methods to detect mosaicism in high-
throughput sequencing data tend to use one of two approaches: (1) paired-sample (tumor/normal) 
and (2) single-sample {Xu 2018}.  Paired-sample approaches are most commonly used in cancer 
where DNA is extracted from tumor and benign (normal) tissue and compared to identify tumor-
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specific mutations of clinical interest.  Methods in this space generally focus on distinguishing 
low allele fraction mosaics from technical noise and can be broadly classified into heuristic 
approaches (e.g. VarScan2{Koboldt 2012}, VarDict {Lai 2016}), joint genotyping-based 
approaches (e.g. SomaticSniper {Larson 2012}, JointSNVMix2 {Roth 2012}), and allele 
frequency-based approaches (e.g. MuTect {Cibulskis 2013}, LoFreq {Wilm 2012}, Strelka 
{Saunders 2012}).  Heuristic approaches identify candidate variants on the basis of alternate 
allele read support and variant allele fraction and use tests such as Fisher’s Exact Test comparing 
the allelic depth (REF, ALT) between tumor and normal samples to test for nonrandom 
association {Koboldt 2012}.  Joint genotyping-based approaches use Bayesian comparisons of 
the genotype likelihoods in tumor and normal samples to identify candidate mosaics {Larson 
2012}.  Allele-frequency-based approaches model joint allele fractions and formulate somatic 
variant calling as a 2-model (wild-type vs. mutant) comparison problem, with candidate mosaics 
variants identified on the basis of log likelihood score {Cibulskis 2013}.  Single-sample methods 
(e.g. SomVarIUS {Smith 2016}, Somatic-Germline-Zygosity {Sun 2018}, MosaicHunter 
{Huang 2017}) have been used in cancer and other settings where paired normal tissues are not 
always available.  These methods typically perform somatic-germline classification using a 
probabilistic framework involving estimating the sequencing error probability and the probability 
of being germline for each variant and identifying candidate mosaics using pre-defined 
thresholds {Smith 2016}.  While existing approaches tend to perform well in resolving low allele 
fraction mosaics, distinguishing high allele fraction mosaics from germline variants remains a 
challenge. 
Mosaicism in heart disease is still an emerging area of research.  The earliest studies 
involved sequencing paired blood and tissue samples from a small number of patients with 
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Ventricular Tachycardia {Lerman 1998} or Atrial Fibrillation {Gollob, Bai 2015}.  Priest et al. 
in 2016 implicated a mosaic SCN5A mutation in Long-QT Syndrome by applying a battery of 
sequencing techniques to blood, urine, and saliva samples from a single patient, followed by 
confirmatory RNA-seq of matched heart tissue.  While these studies advanced our understanding 
of the genetics underlying various forms of cardiovascular disease, they were limited in sample 
size and throughput.  The most recent large-scale study of mosaicism in congenital heart disease 
{Manheimer 2018} analyzed exome-sequencing data of blood samples belonging to 715 proband 
parent trios, followed by confirmation via digital-droplet PCR.  While Manheimer et al. did not 
find that mosaics contributed significantly, limitations in terms of sample size, detection method, 
and validation rate suggest that future investigations into the role of mosaicism in CHD stand to 
benefit from a more systematic approach to mosaic detection involving larger study cohorts and 
different tissue types.   
 
0.3 Organization of this dissertation 
The remainder of this dissertation is organized into two chapters. 
In Chapter 1, I will discuss a new method for the detection of mosaic single-nucleotide 
variants in exome-sequencing data of blood and the implications of mosaicism for congenital 
heart disease.  Briefly, we developed a new computational method, EM-mosaic, that detected 
mosaicism CHD patients with 90% validation rate.  We found that in genes related to CHD, 
mosaic variants predicted to be deleterious had higher allele fraction than those predicted to be 
benign, suggesting presence in a larger fraction of the cells in the individual, earlier occurrence 
in development, and a role in disease.  Detected mosaics comprised 10.4% of apparent de novo 
SNVs and occurred at a frequency of 0.122/exome.  Twenty-five patients in our cohort (1%) 
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carried a plausible disease-causing mosaic event, all of which were independently confirmed.  
Analysis of individuals with matched blood and cardiac tissue available supported the notion that 
mosaic mutations in blood samples with relatively high allele fraction were more likely to also 
be detected in the heart. 
 In Chapter 2, I discuss a statistical approach to investigating association between genetic 
variation and poor clinical outcomes in congenital heart disease patients.  We examined the 
contribution of de novo variation to comorbid neurodevelopmental disorder (NDD) and 
abnormal ventricular function phenotypes by gene set and found that pleiotropic mutations 
contribute a large fraction of the risk.  We also developed a proof-of-concept rare variant risk 
score combining information from de novo, inherited, and copy-number variants and 
demonstrate its utility in predicting NDD in CHD patients, particularly those with Complex or 












Chapter 1: EM-mosaic: Expectation-Maximization-based detection 
of mosaicism  
In this section, I discuss the development of a computational method, EM-mosaic 
(Expectation-Maximization-based detection of Mosaicism), to detect mosaic single nucleotide 
variants (SNVs) using whole-exome sequencing data (WES) of proband and parent DNA. We 
evaluated our method using a simulation experiment to measure the accuracy of its mosaic 
fraction estimation and its posterior odds-based false discovery rate estimation.  To optimize this 
method, we also measured mosaic detection power as a function of variant allele fraction and 
sequencing depth. We then compared EM-mosaic against an existing method, MosaicHunter 
{Huang 2014}, and applied both methods investigate mosaicism in 2530 CHD proband-parent 
trios from the Pediatric Cardiac Genomics Consortium (PCGC) {Jin 2017}, using exome 
sequences derived from blood-derived DNA.  We detected predicted deleterious mosaic 
mutations in genes involved in known biological processes relevant to CHD or developmental 
disorders in 1% of probands. The accuracy of these mosaic variant detection algorithms was 
assessed using an independent re-sequencing method. We found that among high-confidence 
mosaic mutations in CHD-relevant genes, likely-damaging variants tended to have higher VAF 
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than likely-benign variants. In parallel, we assessed mosaicism by applying EM-mosaic and 
MosaicHunter to 70 discarded tissues from several heart regions obtained from 66 probands who 
underwent cardiac surgical repairs. While VAF varied significantly (>3 fold) between blood and 
cardiovascular tissue at about 60% of sites, in general mosaic variants with high (>15%) VAF 
were more likely shared between blood and cardiac tissue than variants with lower VAF. 
1.1 Introduction 
Mosaicism results from somatic mutations that arise post-zygotically in an early 
embryonic cell, resulting in two or more cell populations with distinct genotypes in the 
developing embryo {Biesecker 2013}. The developmental status of the early embryonic cell at 
the time of mutagenesis determines the proportion of variant-carrying cells and the tissue 
distribution of these cells in the post-natal child {Acuna-Hidalgo 2015}. While germline variants 
have a variant allele frequency (VAF) of 0.5, somatic mosaic variants have a significantly lower 
VAF. 
Post-zygotic mosaic mutations have been implicated in several diseases including non-
malignant developmental disorders such as overgrowth syndromes {Poduri 2013; Lindhurst 
2012; Kurek 2016}, structural brain malformations {Poduri 2012; Jamuar 2014; Riviere 2012; 
Lee 2012}, epilepsy {Stosser 2018}, and autism spectrum disorder {Lim 2017; Krupp 2017; 
Freed 2016; Dou 2017}. Recent analyses also identified mosaic variants in a cohort of patients 
with congenital heart disease (CHD) {Manheimer 2018}, but the prevalence of these was far less 
than germline variants (CHD) {Zaidi 2013; Homsy 2015; Jin 2017; Zaidi 2017}.  
Assessment of the frequency of mosaicism in human disease is confounded by technical 
issues, including differences in sequencing depth, DNA sources, and variant assessment 
pipelines. Low levels of mosaicism can escape the detection threshold of traditional sequencing 
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methods with standard read depths, while post-zygotic mutations with a higher percentage of 
affected cells are difficult to discriminate from germline de novo mutations {Acuna-Hidalgo 
2015}. All of these issues can lead to substantially different conclusions. For example, analyses 
of mosaicism in autism spectrum disorder was recently assessed from whole exome sequence 
(WES) data from whole blood DNA from 2506 families (proband, parents and unaffected 
sibling; trios and quads) in the Simons Simplex Collection (SSC) {Fischbach 2010}.  The 
primary sequence data were analyzed by three groups; one that identified a protein-coding 
somatic mosaic variant rate of 0.074 per individual {Freed 2016}, another that found a mosaic 
rate of 0.059 per individual {Lim 2017}, and a third group that reported a mosaic rate of 0.125 
per individual {Krupp 2017}. This disparity suggests the need for more systematic mosaic 
mutation detection methods that account for dataset-specific confounding factors. 
By contrast, analyses of affected tissues can improve the sensitivity and specificity of 
detection of somatic mosaicism. In cancer, methods to detect these events, such as MuTect 
{Cibulskis 2013}, compare tumor and benign tissues from the same patient. Mosaicism has also 
been demonstrated from the analyses of unpaired samples with cancer and other pathologies 
{Sun 2018; Huang 2017; Smith 2015} by the demonstration of variants in affected tissues that 
are absent from blood-derived DNA {Symoens 2017; McDonald 2018}. With access to cardiac 
tissues from patients with CHD obtained during surgical repair, we hypothesized that analyses of 
mosaicism in cardiac tissue might improve insights into the causes of this common congenital 
anomaly. As many cardiomyocyte lineages share a mesodermal origin with blood cells but exit 
the cell cycle during embryogenesis, we also sought to determine if mosaicism in the heart 




1.2 Results  
1.2.1 High-accuracy detection of mosaic mutations in WES data using EM-mosaic 
  We analyzed whole exome sequence (WES) data from 2530 CHD proband-parent trios 
{Homsy 2015; Jin 2017} (>Table S1). Among this cohort, 1205 probands had CHD with 
neurodevelopmental disorders (NDD) and/or extracardiac manifestations (EM), 788 had isolated 
CHD at the time of enrollment, 539 had undetermined NDD status due to young neonatal age at 
the time of enrollment, and 9 subjects had incomplete data (>Table S2).  
Previous WES analyses {Jin 2017} identified 1742 germline de novo SNVs among 838 
cases with NDD and/or EM, 516 isolated cases, 644 cases of unknown NDD status, and 7 with 
incomplete data. These de novo variants were identified using the Genome Analysis Toolkit 
(GATK) pipeline {McKenna 2010; DePristo 2011} assuming a germline diploid model in which 
the expected VAF is 0.5. This model has limited sensitivity to detect mosaic mutations for which 
the fraction of alternative allele reads is significantly below 0.5, especially because de novo 
variants with VAF<0.2 were excluded to reduce false discovery.  
To efficiently capture mosaic variants with VAF<0.4, we developed a new method (EM-
mosaic) to detect mosaic variants in WES sequence of a proband and parents (trios). Potential 
mosaic variants were identified in WES sequence data using SAMtools mpileup {Li 2009} with 
settings designed to capture sites with VAF between 0.1-0.4 and merged with the variants found 
by the GATK pipeline {Jin 2017} (>Fig. 1.1) to create a union variant set. To reduce the 
elevated false positive rate inherent in low-VAF calls, we applied a set of empirical filters to 
remove likely technical artifacts due to sequencing errors associated with repetitive and/or low 
complexity sequences. We then manually inspected de novo SNVs with VAF<0.3 (n=582) using 
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IGV and filtered out an additional 188 likely false positives. After preprocessing and outlier 
removal, the remaining 2971 de novo SNVs were used as input to our mosaic detection model.  
Among the 2971 de novo SNVs, this pipeline identified 309 sites as candidate mosaics based on 
posterior odds score (>Fig. 1.2A-B, Table S3), including 50 sites that were previously reported 
as germline de novo variants {Jin 2017}. An additional 86 sites were identified as having 
posterior odds below our threshold of 10 but greater than 1 (>Fig. 1.3A-B), including a ZEB2 
variant with posterior odds 4.7 that was previously confirmed via ddPCR {Manheimer 2018}. 
Among these 86 variants, 53 are likely mosaic and 33 are likely germline (>Fig. 1.3B). We 
chose not to include these sites since there was insufficient evidence to confidently resolve them 




Figure 1.1. EM-mosaic flowchart 
We first processed our SAMtools de novo calls using our upstream filters (n=2396 sites passing all filters). We then 
applied the same upstream filters to the published dnSNVs from Jin et al. (n=2650 sites passing all filters) before 
finally taking the union of these two call sets (n=3192). High-confidence mosaics (n=309) were defined as mosaics 
passing IGV inspection and having posterior odds > 10. Grey text indicates which filters removed candidate mosaic 





Figure 1.2. Mosaic detection by Expectation-Maximization.  
(A) Expectation-Maximization (EM) Estimation to decompose the variant allele fraction (VAF) distribution of our 
input variants into mosaic and germline distributions. The EM-estimated prior mosaic fraction was 12.15% and the 
mean of the mosaic VAF distribution was 0.15. (B) Read depth vs. VAF distrubution of individual variants. The 
blue line denotes mean VAF (0.49) and the red lines denote the 95% confidence interval under our Beta-Binomial 
model. Mosaic variants are defined as sites with posterior odds > 10, corresponding to a False Discovery Rate of 
9.1%.  Germline variants are represented in black and mosaic variants are represented in red. (C) Estimated mosaic 
detection power as a function of average sample depth for values between 40x and 500x. 
 

































Figure 1.3. Blood variants with posterior odds between 1 and 10.  
(A) Distribution of the 86 variants with posterior odds between 1 and 10. (B) Histogram of counts by bin. To 
estimate the number of potential mosaics missed by our threshold, counts of each bin were scaled by the estimated 
true positive rate (TPR; posterior odds / 1+posterior odds). By our estimate, 54/86 variants were likely mosaic and 
32/86 were likely germline. 
 






Mosaic Variants (total)* 315 (332) 56 (57) 218 (240) 29 (35) 
Mosaic Candidates 367 58 251 58 
Mosaic Candidate VAF mean (SD) 0.13 (0.06) 0.12 (0.05) 0.13 (0.06) 0.10 (0.05) 
MiSeq 
Confirmation 
Total Tested 143 22 75 46 
Mosaic 108 21 64 23 
Germline 3 0 3 0 
No Variant 32 1 8 23 
Validation Rate 76% 95% 85% 50% 
*Estimated number of mosaic variants found among 2530 CHD probands (total number of mosaic variants detected by EM-





Figure 1.4. MosaicHunter workflow.  
Quality Control filters excluded any sites that were (1) present in ExAC (2) G>T with Nalt<10 (3) parent Nalt>2. 
Outliers were defined as probands carrying more than 20 mosaics, or non-unique sites. We also removed sites called 
as germline by GATK Haplotype Caller. High-confidence mosaics (n=116) were defined as having Likelihood Ratio 
> 80 and affecting coding regions excluding MUC/HLA genes. Grey text indicates which filters removed variants 








1.2.2 Method evaluation via simulation experiment 
 We evaluated EM-mosaic using a simulation experiment to measure the accuracy of its 
mosaic fraction estimation and its posterior odds-based false discovery rate (FDR) estimation.  
We simulated roughly 1 million variants (Nalt, N) for a range of sample average sequencing depth 
values (40x, 60x, 100x) and spiked in a known fraction of simulated mosaic variants.  We then 
applied EM-mosaic to each dataset and compared the resulting mosaic and germline predictions 
for each variant against their ground truth labels.  We found that our EM-estimated mosaic 
fraction was consistent with the true fraction across all datasets ( 0.3%), with slight 
overestimation at lower sequencing depth (40x) and slight underestimation at higher sequencing 
depth (100x).  We next estimated the false discovery rate (FDR) for each variant as a function of 
posterior odds (1/(1+posterior odds)).  Then, for FDR cutoffs j = {0, 0.01, …, 0.99, 1.0}, we 





  as well as the False Discovery Proportion (FDPj ; the 
fraction of variants with a ground truth label of “germline”) using the N variants with FDR < j.  
We found that our posterior odds-based FDR estimates were consistent with the true FDR values 
(>Fig. 1.5C).  Simulation experiment results for the 60x dataset (representative of the sequencing 
depth used for the CHD patient cohort) are summarized in Figure 1.5; results from the other 




Figure 1.5. Simulation experiment results (60x dataset).   
(A) We simulated n=1,015,017 variants at sample average sequencing depth 60x (n=900,439 germline, n=114,470 
mosaic). (B) Our EM approach accurately estimated mosaic fraction (simulated = 11.28%, inferred = 11.23%).  (C) 
Our posterior-odds-based FDR was consistent with the FDR as determined from the ground truth variant labels (# 





Est. Mosaic Fraction = 0.1122
True Fraction = 0.1128
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1.2.3 Mosaic mutations found in blood derived DNA with MosaicHunter  
We also employed MosaicHunter, which uses a Bayesian genotyping algorithm with a 
series of stringent filters (see Materials and Methods) for discovering mosaic variants using 
WGS genotype information from trios. {Huang 2017} Among the 2530 CHD trios, 
MosaicHunter identified an initial set of 58976 sites showing evidence of mosaicism, including 
214 high-confidence variants located in coding regions. (>Fig. 1.4). After applying a minimum 
likelihood ratio (LR) cutoff of 80 for distinguishing mosaic from germline mutation, and 
additional heuristic filters (Materials and Methods), MosaicHunter identified 116 coding sites 
(>Table S4) or 0.05 mosaics /individual. 
Of the mosaic candidates detected by MosaicHunter, 58/116 (50%) were also identified 
by EM-mosaic while 58/116 (50%) candidates were unique to MosaicHunter (>Table 1.1). Of 
the 58 candidates unique to MosaicHunter, 35 were filtered out by EM-mosaic on the basis of 
insufficient alternate allele read support, 16 had a non-zero allelic depth in the parents, and 7 
failed quality filters. The 251 candidates unique to EM-mosaic were discarded by the 
MosaicHunter pipeline during BAM reprocessing (n=13), quality filtering (n=146), application 
of LR cutoff (22), or were not called due to inadequate read depth (n=70) (>Fig. 1.4).  
 
1.2.4 Sequence confirmation of candidate mosaic variants and estimation of mosaicism in 
CHD  
From the 367 high-confidence EM-mosaic and/or MosaicHunter SNVs, we selected 143 
candidates (97 identified by EM-mosaic; 68 identified by MosaicHunter) for experimental 
confirmation using MiSeq amplicon resequencing (>Table S5; Tables S11 and S12; Methods). 
DNA fragments encompassing the putative mosaic variant were PCR-amplified from proband 
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and each parent DNA, sequenced on an Illumina MiSeq next generation sequencer and VAF was 
calculated for each individual. These candidate mosaics included SNVs on the extremes of the 
VAF spectrum, as well as mosaics that were flagged by MosaicHunter quality filters. Candidates 
mosaic variants were considered confirmed by MiSeq analyses if they demonstrated an amplicon 
VAF exceeding 0.01 but less than 0.45, so as to indicate a variant of post-zygotic origin. MiSeq 
VAF values closely correlated with those originally determined by exome sequencing (P= 
2.2x10-16; >Fig. 1.6). 
We confirmed 85/97 (88%) EM-mosaic candidate mosaic variants. Three candidate 
variants were likely germline de novo SNVs (VAF>0.45). Nine candidate variants were ‘false 
positives’ that were neither germline de novo SNVs or mosaic SNVs since either no variant 
reads were detected by MiSeq sequencing of the proband amplicon, or the same small fraction of 
variants were detected in proband amplicon and one parent’s amplicon.  
  Parallel analyses with MosaicHunter confirmed 44/68 (65%) candidate mosaic variants. 
There were 23 sites for which no variant reads were detected by MiSeq amplicon sequencing 
(MiSeq VAF<0.001) or in which the same small fraction of variant reads was detected in the 
proband amplicon as in one parent’s amplicon.   
 We considered whether estimates of mosaic variant frequency were sensitive to whole 
exome sequencing depth by calibrating estimates of mosaic detection power using properties of 
the sequence data (average read depth, prior mosaic fraction, and the value of our overdispersion 
parameter θ) (>Fig. 1.16; Materials and Methods). Our projected mosaic detection power curves 
demonstrated more than a doubling of power to detect mosaic variants with VAF 0.2 as 
sequencing depth increases from 40x to 80x (>Fig. 1.2C). Projected mosaic detection power 
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curves for less stringent mosaic cutoffs showed similar increases of power with increasing 
sequencing depth (>Fig. 1.7). 
  To estimate the ‘true’ frequency of mosaicism per blood DNA exome, independent of 
average coverage detection power constraints, we estimated the ‘true’ mosaic count in a VAF 
range by multiplying the number of mosaics by the inverse of the detection power for each VAF 
bin. Applying this method to the 184 of 309 high-confidence EM-mosaic variants with 
VAF>0.1, we estimated the adjusted number of mosaics with VAF>0.1 to be 361 (>Fig. 1.7A). 
Thus, the true frequency of coding mosaics in the blood (0.4>VAF >0.1) is 0.14 variants per 
individual, representing a non-negligible class of mutations with potential contribution to genetic 
risk for congenital heart disease. The estimated true mosaic frequency does not change 
significantly when using less stringent mosaic definitions (>Fig. 1.7B-C). In sum, we identified 
315 blood mosaic variants in 2530 CHD probands or 0.13 mosaic variants per subject with a 
mean VAF of 0.13±0.06. We do not anticipate that doubling the sequencing depth would change 






Figure 1.6. Targeted sequencing to validate candidate blood mosaic variants.  
(A) EM-mosaic and (B) MosaicHunter variants were assayed using PCR followed by MiSeq for high-depth 
assessment of mosaicism. Variants with x symbols were shared by both pipelines. Mosaic variants that validated are 
black, while variants with VAF > 0.45 and therefore germline are red. Validation VAF values demonstrated 
significant correlation with the original WES-derived VAF for EM-mosaic (Pearson’s correlation P=2.2x10-16) and 
MosaicHunter (P=8.2x10-11).  (C) We observed an inflation of VAF when comparing MiSeq against WES data, 

































































































Figure 1.7. Estimated mosaic detection power using less stringent mosaic definitions.  
(A) Estimated true frequency of detectable coding mosaics (0.4>VAF>0.1) adjusted by detection power (n=341; 
0.135/exome) (B) Calibrated mosaic detection power and estimated true mosaic frequency of detectable coding 





































































































































































































































1.2.5 Mosaic variants occurred most frequently at CpG sequences. 
 Previous studies demonstrated a strong preference for de novo C>T mutations at CpG 
dinucleotides compared to other dinucleotides due to the spontaneous deamination of 5-
methylcytosine {Fryxell 2005; Francioli 2015}. We asked whether the germline de novo variants 
observed in CHD probands and the 332 mosaic sites demonstrated a similar sequence preference 
(>Fig. 1.8, Table 1.1, Tables S3 and S4). Of the 2662 germline de novo mutations identified in 
2530 CHD probands, 979 variants (37% of all variants) involved mutation of the cytosine of a 
CpG dinucleotide (>Fig. 1.8A). By contrast, 99 (29% of all mosaic SNVs) of 332 mosaic SNVs 
altered the cytosine of a CpG dinucleotide more than expected by chance (2.2x above 
expectation; p=2.0E15). Ignoring the high CpG mutation frequency, cytosines and guanines were 
~2-fold more likely to be mutated than adenines or thymidines both for germline mutations and 
for mosaic variants. Surprisingly, somatic mutations of A>C/T>G transversions in ApC 
dinucleotides were ~2-fold greater than the corresponding germline mutations (P=5x10-8; >Fig. 
1.8B).  
  
Figure 1.8. Mutation spectrum of detected germline and mosaic variants.  
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Rates of specific mutations for (A) germline, (B) blood mosaic, and (C) CHD tissue mosaic variants. Transitions 
predominated in both variant sets. 
 
 
1.2.6 Detection of mosaic mutations in CHD tissues 
  Using EM-mosaic and MosaicHunter we analyzed exome sequences from 70 cardiac 
tissues derived from 66 subjects with CHD (>Table S6) and paired blood samples. Among 57 de 
novo variants (allele depth approximately 0.5) that were previously identified in blood-derived 
DNA, 54 were also found in CHD tissues. Of the 3 de novo variants not present in cardiac tissue, 
1 was outside of the tissue WES capture region and 2 occurred in a single proband (>Table 1.2). 
In addition, 23 distinct candidate mosaic variants were detected by EM-mosaic (n=13), 
MosaicHunter (n=6), or by both algorithms (n= 4). All 23 candidates were tested via MiSeq 
amplicon sequencing of blood and cardiac tissue DNAs; 15 of 23 unique candidate mosaics were 
confirmed (>Table 1.2, S7), including a CCNC variant that was identified in two different CHD 
tissues from proband 1-01684. Ten (86%) confirmed mosaic variants were detected in blood and 
cardiac tissues (MAF>0.01), four were found only in cardiac tissue, and one was found only in 
blood. Of the 7 mosaics detected by blood WES analysis, 4 were confirmed in the corresponding 
cardiac tissue sample.  Remarkably, five confirmed cardiac tissue mosaic variants occurred in 
one proband (1-07004), one of which was also present in blood DNA.  
These analyses indicate a frequency of coding mosaics (0.4>VAF >0.1) in the cardiac 
tissues of 0.14 per individual (9 of 66 probands), which approximated our estimate of 0.14 blood 
mosaics per individual (>Fig. 1.7A). Despite these similar frequencies, multiple distinct mosaic 
variants were identified in these tissues. Mosaics with highest VAF were more likely to be found 
in both tissues (Mann-Whitney U Test P=0.019), presumably indicating that the mutation 




Figure 1.9. Validated mosaics detected in probands with matched blood and cardiovascular tissue 
samples available.  
Validation VAF from blood compared to validation VAF from cardiovascular tissue demonstrated tissue-specific 








Validation VAF from (A) cardiovascular tissue and (B) blood had higher VAF for shared variants compared to 
tissue-specific variants (p=0.101 and 0.015, respectively). 
 



















1-00543 CTCFL Bmis EM-mosaic AO 138,36 0.21 0.32 29,8 0.22 0.19 
1-00984 ZNF16 syn EM-mosaic LV 262,1 0.00 0.01 100,7 0.07 0.07 
1-01282 GABRA6 Dmis MosaicHunter RV 104,1 0.01 0.01 55,12 0.18 0.18 
1-01684 CCNC Bmis Both AoValve, RV 36,7 0.16 0.17, 0.19 224,40 0.15 0.14 
1-02672 TOR1A syn Both AtrSpt 159,10 0.06 0.10 29,6 0.17 0.19 
1-03512 RFX3 LoF MosaicHunter RV 156,15 0.09 0.08 39,0 0.00 0.03 
1-04652 PCDH10 syn Both AtrSpt 154,19 0.11 0.14 15,1 0.06 0.10 
1-07004 ANK2 Bmis MosaicHunter SubAoMembr 226,13 0.05 0.04 30,0 0.00 0.00 
1-07004 MYH14 Bmis Both SubAoMembr 124,22 0.15 0.27 33,0 0.00 0.00 
1-07004 NRG3 Bmis EM-mosaic SubAoMembr 152,30 0.16 0.24 43,0 0.00 0.00 
1-07004 NUDT21 Bmis Both SubAoMembr 137,22 0.14 0.14 74,0 0.00 0.02 
1-07004 TET3 Dmis MosaicHunter SubAoMembr 131,1 0.01 0.03 81,16 0.16 0.27 
1-07299 RRS1 syn Both RV, UNK 160,25 0.14 0.25 22,2 0.08 0.14 
1-09869 PIK3C2G LoF MosaicHunter LV 126,9 0.07 0.10 31,0 0.00 0.00 
1-11800 TMEM45A Bmis MosaicHunter RV 213,0 0.00 0.00 32,7 0.18 0.06 
 
Characteristics of mosaic variants predicted for individuals with blood and cardiovascular tissue WES data 
available. Among 15 mosaics, 5 were detected via analysis of blood WES, 8 were detected from cardiovascular 
tissue WES, and 2 were detected by both approaches. Six of 7 (86%) mosaics detected from analysis of blood were 
present in both DNA sources with MiSeq VAF≥0.01. Two additional variants previously identified as de novo 
germline variants in blood WES were absent from CHD tissue WES. Minimum 1023 MiSeq reads used to determine 
VAF. Abbreviations: AD, allelic depth (reference, alternate); AO, aorta; AtrSpt, atrial septum; Bmis, benign 
missense; Dmis, deleterious missense; LOF, Loss of function variant; LV, left ventricle; RV, right ventricle; VAF, 
variant allele fraction. 
 
1.2.7 Blood and cardiac tissue mosaics likely to contribute to CHD 
Our prior genetic studies of CHD studies showed that damaging de novo variants 
typically occurred in genes highly expressed in the top quartile of the developing E9.5 mouse 
heart (HHE) {Zaidi 2013; Homsy 2015} or that contribute to CHD in mouse models {Jin 2017}. 
Among the 342 mosaic variants identified from blood or cardiac tissue analyses that were not 
false by MiSeq, 65 altered these HHE and/or mouse CHD genes (n=4558, >Table S8). RefSeq 
functional annotation predicted 52 variants as likely-damaging variants (LOF, Dmis), and 46 as 
likely benign, missense (>Tables S8, S9). In total, we observed potentially CHD-causing mosaic 
mutations in 25 participants, representing 1% of the 2530 total participants in our CHD cohort. 
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Among these 25 mosaics, we confirmed 22/22 (100%) candidates tested via MiSeq.  Notably, 
multiple likely-damaging mosaic variants altered genes (ISL1, SETD2, NOVA2, SMAD9, LZTR1, 
KCTD10, KCTD20, FZD5, and QKI) involved in key developmental pathways, which may 
account for the extra-cardiac phenotypes observed in these patients (>Table 1.3, S10). There was 
no difference in the proportion of individuals with extracardiac features among those with 
damaging mosaic variants compared to the overall cohort (11/25 vs 909/ 2521, P=0.68), and 
there was a wide range of CHD subtypes.  Five subjects carried additional de novo LoF or Dmis 
variants (1-06216, TYRP1; 1-04046, KRT13; 1-06677, TRIP4; 1-05011, KDM5B; 1-00018, 
SBF1) and 4 genes harbored de novo LoF or Dmis variants other than those listed in Table 1.3 
(FBN1; PKD1; LZTR1; PIK3C2G). No CNVs were detected in these subjects, with the 
exception of 1-00192 (duplication at chr15:22062306-23062355; non-overlapping with the 
GLYR1 mosaic). 
If mosaic variants were unrelated to CHD, we would expect similar allelic fractions 
between mosaics with variants predicted as likely damaging or likely benign. However, we 
found that the allele fraction of likely damaging variants was significantly higher (Mann-
Whitney U Test P=0.001, >Fig. 1.11A). Moreover, among mosaic variants in genes that are not 
included among HHE or mouse CHD genes, we found no significant difference of allele fraction 
(P=0.985, >Fig. 1.11B). We repeated these analyses using less stringent posterior odds cutoffs of 
2 and 5 and found the same result (>Fig. 1.12). Together these data support our conclusion that 
at least some likely-damaging mosaic variants identified here contribute to CHD.  These results 




Figure 1.11. Damaging mosaics in CHD-related genes have higher variant allele fraction than 
likely-benign mosaics.  
(A) Among the 76 mosaics in CHD-related genes, likely damaging variants have a higher VAF than likely benign 
(Mann-Whitney U p=0.001). (B) Among the 233 mosaics in Other (non-CHD-related) genes, there is no difference 
in VAF based on predicted effect (p=0.985). 
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Figure 1.12. Damaging CHD-related mosaics have higher VAF under less stringent definitions of 
mosaicism.  
(A) Using posterior odds cutoff of 5 (corresponding to 315 mosaics). Among 78 mosaics in CHD-related genes 
(left), there were 14 variants predicted as damaging, 63 variants predicted as likely-benign, and 1 variant of 
unknown functional consequence. Among 237 mosaics in non-CHD-related genes (right), there were 41 variants 
predicted as damaging, 184 variants predicted as likely-benign, and 2 variants of unknown functional consequence. 
(B) Using posterior odds cutoff of 2 (corresponding to 352 mosaics). Among 89 mosaics in CHD-related genes 
(left), there were 17 variants predicted as damaging, 71 variants predicted as likely-benign, and 1 variant of 
unknown functional consequence. Among 263 mosaics in non-CHD-related genes (right), there were 54 variants 
predicted as damaging, 206 variants predicted as likely-benign, and 3 variants of unknown functional consequence. 
|| | | || || | || || ||| || || ||| | || || ||| || ||| |||| |||
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Table 1.3. Damaging Mosaics in CHD-relevant genes 
ASD, atrial septal defect; BAV, bicuspid aortic valve; Dmis, deleterious missense; episcore, haploinsufficiency score 
(percentile rank) {Han 2018}; Heart Exp, heart expression percentile rank; LoF, loss-of-function; pLI, probability 
of loss-of-function intolerance {gnomAD}; PCGC, Pediatric Cardiac Genomics Consortium; VAF, variant allele 
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Figure 1.13. Mosaic rate by proband age.  
(A) Age distribution for all 2530 probands in cohort. (B) Mosaic Rate across Age ranges. Rate = # mosaics/# 




Figure 1.14. Mosaic rate by parental age at birth.  
Mosaic rate by age of father (blue) and mother (red) at birth. Rate = # mosaics/# probands in each parental age bin. 







































1.3 Discussion  
Distinguishing mosaic mutations from constitutional mutations has both clinical 
management and reproductive implications for proband and parents. Individuals with mosaic 
mutations are generally clinically less severely affected for conditions that affect multiple parts 
of the body {Happle 1986; Wallis 1990; Cohn 1990; Etheridge 2011; Donkervoort 2015; 
Weinstein 2016}. Mutations that occur post-zygotically should have no recurrence risk for the 
parents and could have a recurrence risk of less than 50% for the proband depending on gonadal 
involvement. This study is among the first investigations of the role of post-zygotic mosaic 
mutations in CHD. We developed a new computational method to robustly detect mosaic single 
nucleotide variants from blood WES data at standard read depth. Applying this method to a 
cohort of 2530 CHD patients, we detected 309 high-confidence mosaics (with a confirmation 
frequency of 88% in a subset of variants assessed) or 0.12 variants per proband.  Sequencing of 
cardiac tissue to greater depth identified an additional 8 mosaic variants that had not been 
detected in blood WES, 6 of which are present in cardiac tissue but not blood. We found 
significantly more variants per proband in cardiac tissue DNA (0.23 variants per proband) than 
in blood DNA (0.12 variants per proband; p=0.02). While the increased numbers of mosaic 
variants in cardiac tissue DNA vs blood DNA may reflect technical differences such as 
sequencing read depth of cardiac tissue DNA vs blood DNA, it is possible that somatic variation 
occurs more frequently in cardiac tissue of CHD probands than in their blood. Whether or not 
there are more cardiac tissue mosaic variants in CHD probands than blood DNA variants, we 
found 10 mosaic variants among 66 CHD proband cardiac tissues with a higher VAF in tissue 
than in blood (Table 1.2) and 5 variants among these individuals with a higher VAF in blood 
than in tissue.  
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In total, we observed potentially CHD-causing mosaic mutations in 25 participants, 
representing 1% of the 2530 total participants in our CHD cohort. Among these 25 mosaics, we 
confirmed 22/22 (100%) candidates tested.  We found that in CHD-related genes, likely-
damaging mosaic mutations have significantly greater alternative allele fraction than likely-
benign mosaics, suggesting that some of these variants contribute to CHD. Comparison of blood 
and cardiovascular tissues demonstrated tissue-specific mosaic variants, though those variants 
with a higher VAF were more likely to be shared between tissues. Due to limitations of 
conventional clinical interpretation for both mosaic and constitutional CHD variants (Materials 
and Methods), we cannot know with complete certainty which among these 25 variants is 
pathogenic and instead propose that, among our detected mosaics, the 23 detected from blood 
WES data provide an estimate of the disease-causing mosaics detectable in blood with standard 
exome-sequencing read depth. Nine of these variants affect genes known to have a role in 
cardiac development: ISL1, SETD2, NOVA2, QKI, SMAD9, LZTR1, KCTD10, KCTD20, and 
FZD5.  
The mosaic LOF mutation in ISL1 is likely to be the cause of CHD in participant 1-
05095. ISL1 is a transcription factor essential to normal cardiac development that regulates 
expression of NKX, GATA, and TBX family genes {Golzio 2012; Colombo 2018} and controls 
secondary heart field differentiation and atrial septation {Colombo 2018; Briggs 2012}. ISL1 
deficiency has been shown to lead to severe CHD in mice {Cai 2003; Golzio 2012}. Participant 
1-05095 has an isolated atrial septal defect consistent with a secondary heart field defect 
phenotype {Stevens 2010} and has no other previously reported damaging germline variants in 
CHD-related genes.  
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Damaging germline de novo variants in CHD subjects are enriched in genes related to 
chromatin modification and RNA processing {Homsy 2015; Jin 2017}. Three genes with 
damaging mosaic variants discovered here have related functions. SETD2 is a histone 
methyltransferase required for embryonic vascular remodeling {Hu 2010}; it is both sensitive to 
haploinsufficiency and highly expressed in the heart during development. NOVA2 is a key 
alternative-splicing regulator involved in angiogenesis that has been shown to disrupt vascular 
lumen formation when depleted {Giampietro 2015}. QKI encodes an RNA-binding protein that 
regulates splicing, RNA export from the nucleus, protein translation, and RNA stability {Lauriat 
2008}. QKI is also highly expressed in the heart during development and has been shown to 
cause CHD and other blood vessel defects in mice when dysregulated {Noveroske 2002}.  
Other damaging mosaic variants affect processes known to be relevant to CHD. SMAD9 is 
involved in the TGF-beta signaling pathway. TGF-beta signaling plays a critical role in cardiac 
development and cardiovascular physiology, leading to pulmonary arterial hypertension and 
cardiac abnormalities in mice when dysregulated {Drake 2015; Soubrier 2013}. LZTR1 encodes 
a member of the BTB-Kelch superfamily that is highly expressed in the heart during 
development and has been associated with Noonan {Yamamoto 2015; Ghedira 2017} and 
DiGeorge Syndromes {Kurahashi 1995}, both of which are characterized by CHD. KCTD10 
binds to and represses the transcriptional activity of TBX5 (T-box transcription factor), which 
plays a dose-dependent role in the formation of cardiac chambers {Tong 2014}. KCTD10 is 
highly expressed in the heart during development and has been shown to produce CHD in mice 
when dysregulated {Ren 2014}. KCTD20 is a positive regulator of Akt {Nawa 2013} also highly 
expressed in the heart during development. FZD5 is haploinsufficient and encodes a 
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transmembrane receptor involved in Wnt, mTOR, and Hippo signaling pathways and has been 
shown to play a role in cardiac development {Dawson 2013}. 
Finally, two mosaic variants found in cardiac tissue, genes encoding RFX3 and 
PIK3C2G, may be disease-relevant. PIK3C2G is a signaling kinase involved in cell proliferation, 
survival, and migration, as well as oncogenic transformation and protein trafficking {OMIM: 
609001; RefSeq}. The effects of PIK3C2G haploinsufficiency during cardiac development has 
not been characterized. RFX3 is a highly-constrained ciliogenic transcription factor that leads to 
pronounced laterality defects {Rasmdell 2005} and disruption of RFX3 leads to congenital heart 
malformations in mice {Lo 2011 MGI: 5560494}. Notably the RFX3 LoF variant has a 4-fold 
higher VAF in cardiac tissue than in blood.  
Several investigators who studied cancer and diseases with cutaneous manifestations 
proposed that the VAF correlates with time of mutation acquisition and disease burden 
{Belickova 2016; Sallman 2016; Happle 1986}. In this study, we used VAF as a proxy for 
cellular percentage and mutational timing, with increasing VAF corresponding to events 
occurring earlier in development. Thus, we assume that CHD-causal mosaic events identified in 
blood-derived DNA occurred during or shortly after the gastrulation process (3rd week of 
development) {Moorman 2003} in the mesodermal progenitor cells that differentiate into both 
heart precursor cells (cardiogenic mesoderm) and blood precursor cells (hemangioblasts). We 
found that in CHD-relevant genes, mosaic sites predicted to be damaging tended to have higher 
VAF than sites predicted to be likely benign, consistent with the hypothesis that these mutations 
arose early in fetal development and play significant roles in CHD. However, additional 
functional studies are necessary to fully assess causality.  
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Finally, we recognize that while our method is able to detect a large fraction of mosaic 
variants in blood, our calibrated estimates for the true number of mosaics suggest there are a 
non-negligible number of additional mutations that were not identified by our method. At our 
current average sequencing depth of 60x, we have limited sensitivity in the low VAF (<0.05) 
range. To reliably identify these low allelic fraction sites, ultra-deep sequencing will be critical to 
distinguishing true variants from noise. At 500x, we estimate detection sensitivity for mosaic 
events at VAF 0.05 to be above 80%. We also recognize age-related clonal hematopoiesis 
{Jaiswal 2014; Genovese 2014} as a potential confounding factor in somatic mutation detection; 
however, our study cohort includes mostly pediatric cases and we did not observe mosaic 
mutations in genes related to clonal expansion (e.g. ASXL1, DNMT3A, TET2, JAK2) nor did we 
observe a relationship between proband age and mosaic rate (>Fig. 1.13, Fig. 1.14), suggesting 
minimal impact from this process.  
This study is among the first investigations of the role of post-zygotic mosaic mutations 
in CHD. Despite limitations in sequencing depth and sample type, EM-mosaic was able to detect 
309 high-confidence mosaics with resequencing confirmation in 88% of cases assessed. Using 
MosaicHunter, an additional 64 candidate mosaic sites were identified, of which 23/46 (50%) 
candidates from blood DNA and 4/6 (67%) from CHD tissue DNA validated. In total, we 
observed potentially CHD-causing mosaic mutations in 25 participants, representing 1% of our 
CHD cohort, and propose that these 25 cases provide an estimate of the disease-causing mosaics 
detectable in blood with standard exome-sequencing read depth. Additionally, we found that in 
CHD-related genes, likely-damaging mosaics have significantly greater alternative allele fraction 
than likely benign mosaics, suggesting that many of these variants cause CHD and occurred 
early in development. In the subset of our cohort for which cardiovascular tissue samples were 
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available, we show that mosaics detected in blood can also be found in the disease-relevant tissue 
and that, while the VAF for mosaic variants often differed between blood and cardiovascular 
tissue DNA, variants with higher VAF were more likely to be shared between tissues. Given 
current limitations in sequencing depth and on the availability of relevant tissues, particularly for 
conditions impacting internal organs like the heart, the full extent of the role of mosaicism in 
many diseases remains to be explored. However, as datasets containing larger numbers of blood 
and other tissue samples sequenced at higher depths become increasingly available, we will be 
able to more fully characterize the biological processes underlying post-zygotic mutation and, by 
extension, the contribution of mosaicism to disease using the methods presented here. 
 
1.4 Materials and Methods 
1.4.1 Samples and sequencing data 
We analyzed WES data from 2530 Congenital Heart Disease (CHD) proband-parents trio 
families who were recruited as part of the Pediatric Cardiac Genomics Consortium (PCGC) 
study {Homsy 2015; Jin 2017}. Genomic DNA from venous blood or saliva was captured using 
Nimblegen v.2 exome capture reagent (Roche) or Nimblegen SeqCap EZ MedExome Target 
Enrichment Kit (Roche) followed by Illumina DNA sequencing (paired-end, 2x75bp) {Jin 2017, 
Zaidi 2013}. Genomic DNA from 70 surgically-discarded cardiovascular tissue samples (2-
10mg) was isolated using DNeasy Blood & Tissue Kit (QIAgen), then captured using xGen 
Exome Research Panel v1.0 reagent (IDT) followed by Illumina DNA sequencing (paired-end, 
2x75bp). Sequence reads were mapped to the hg19 human reference genome with BWA-MEM 
and BAM files were further processed following GATK Best Practices, which included 
duplication marking, indel realignment, and base quality recalibration steps. Blood and saliva 
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samples had sample average depth 60x and cardiovascular tissue samples had sample average 
depth 160x. 
 
1.4.2 De novo variant calling and annotation 
  We processed our sample BAMs and called variants on a per-trio basis using SAMtools 
(v1.3.1-42) and BCFtools (v1.3.1-174). Pileups were generated using samtools ‘mpileup’ 
command with mapQ 20 and baseQ 13 to minimize the effect of poorly mapped reads on variant 
allele fraction, followed by bcftools ‘call’ using a cutoff of 1.1 for the posterior probability of the 
homozygous reference genotype parameter (-p) to capture additional sites with variant allele 
fraction suggestive of post-zygotic origin that would otherwise be excluded under the default 
threshold of 0.01. To identify de novo mutations from trio VCF files, we selected sites with (i) a 
minimum of 6 reads supporting the alternate allele in the proband and (ii) for both parents, a 
minimum depth of 10 reads and 0 alternate allele read support. Variants were then annotated 
using ANNOVAR (v2017-07-17) to include information from refGene, gnomAD (March 2017), 
1000 Genomes (August 2015), ExAC, genomicSuperDups, CADD (v1.3) COSMIC (v70), and 
dbSNP (v147) databases, as well as pathogenicity predictions from a variety of established 
methods included as part of the dbNSFP (v3.0a) database or generated in-house (MCAP, 
REVEL, MVP, MPC). We used REVEL {Ionnidis 2016} to evaluate missense variant functional 
consequence, using the recommended threshold of 0.5 corresponding to sensitivity of 0.754 and 
specificity of 0.891. We used spliceAI {Jaganathan 2019} to predict the variant functional 
impact on splicing using the delta score thresholds of 0.2 for likely pathogenic (high recall), 0.5 
for pathogenic (recommended), and 0.8 for pathogenic (high precision).  We considered sites 
predicted to be Likely Gene-Disrupting (LOF) (stopgain, stoploss, frameshift indels, splice-site), 
42 
 
Deleterious Missense (Dmis; nonsynonymous SNV with REVEL>0.5), or splice-damaging 
(Benign Missense or synonymous SNV with delta score > 0.5) to be damaging and likely disease 
causing. We considered sites predicted to be Synonymous (delta score ≤ 0.5) or Benign missense 
(Bmis; nonsynonymous SNV with REVEL ≤ 0.5 and delta score ≤ 0.5) to be non-damaging. 
 
1.4.3 Pre-processing and quality control 
  To reduce the number of low VAF technical artifacts introduced by our variant calling 
approach, we pre-processed our variants using a variety of filters. We first excluded indels from 
further analysis, as their downstream model parameter estimates were less stable than those of 
SNVs. We then filtered our variant call set for rare heterozygous coding mutations (Minor Allele 
Frequency (MAF) ≤ 10-4 across all populations represented in gnomAD and ExAC databases). 
To account for regions in the reference genome that are likely to affect read-depth estimates, we 
removed variant sites found in regions of non-unique mappability (score<1; 300bp), likely 
segmental duplication (score>0.95), and known low-complexity {Li 2014}. We then excluded 
sites located in MUC and HLA genes and imposed a maximum variant read depth threshold of 
500. We used SAMtools PV4 to exclude sites with evidence of technical issues using a cutoff of 
1e-3 for baseQ Bias and Tail Distance Bias and a cutoff of 1e-6 for mapQ Bias. To account for 
potential strand bias, we used an in-house script to flag sites that have either (1) 0 alternate allele 
read support on either the forward or reverse strand or (2) p<1e-3 and (Odds Ratio (OR)<0.33 or 
OR>3) when applying a two-sided Fisher’s Exact Test to compare proportions of reference and 
alternate allele read counts on the forward and reverse strands. We also excluded sites with 
cohort frequency>1%, as well as sites belonging to outlier samples (with abnormally high de 
novo SNV (dnSNV) counts, cutoff = 8) and variant clusters (defined as sites with neighboring 
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SNVs within 10bp). Finally, we applied an FDR-based minimum Nalt filtering step (>Fig 1.15) to 
control for false positives caused purely by sequencing errors.  
 
Figure 1.15. FDR-based minimum Nalt threshold.  
An FDR-based approach was used to determine a threshold for the minimum number of reads supporting the 
alternate allele for each site to avoid false positives caused purely by sequencing errors. Assuming that sequencing 
errors are independent and that errors occur with probability 0.005, with the probability of an allele-specific error 
being 0.005/3=0.00167, and given the total number of reads (N) supporting a variant site, we iterated over a range of 
possible Nalt values between 1 and 0.5*N and estimated the expected number of false-positives due to sequencing 
error, exome-wide ((1- fPoisson(x=n, λ=N*0.005/3))*3x107 ; where fPoisson is the probability of x events in a Poisson 
process with mean λ). Assuming one coding de novo SNV per exome {Acuna-Hidalgo 2016} and that roughly 10% 
of de novo SNVs arise post-zygotically {Lim 2017; Krupp 2017; Freed 2016}, we used a conservative assumption 
of 0.1 mosaic mutation per exome. To constrain theoretical FDR to 10% we allowed a maximum of 0.01 false 
positives per exome and used the corresponding Nalt value to define an FDR-based minimum Nalt threshold for each 




1.4.4 IGV visualization of low allele fraction de novo SNVs 
To reduce the impact of technical artifacts on model parameter estimation, we manually 
inspected de novo SNVs with VAF<0.3 (n=558) using Integrative Genomics Viewer (v2.3.97) to 
visualize the local read pileup at each variant across all members of a given trio family. We 
focused on the allele fraction range 0.0-0.3 since this range is enriched for technical artifacts that 
could potentially impact downstream parameter estimation. Sites were filtered out if (1) there are 
inconsistent mismatches in the reads supporting the mosaic allele, (2) the site overlaps or is 
adjacent to an indel, (3) the site has low MAPQ or is not Primary alignment, (4) there is evidence 
of technical bias (strand, read position, tail distance), or (5) the site is mainly supported by soft-
clipped reads. 
  
1.4.5 Expectation-Maximization to estimate prior mosaic fraction and control FDR 
  Current estimates for the fraction of de novo events occurring post-zygotically are 
unstable due to differences in study factors such as variant calling methods, average sequencing 
depth, and paternal ages. In order to use this fraction as a prior probability in our posterior odds 
and false discovery calculations, we reason that this value must be estimated from the data itself. 
We used an Expectation-Maximization algorithm to jointly estimate the fraction of mosaics 
among apparent de novo mutations and to calculate a per-site likelihood ratio score. This initial 
mosaic fraction estimate gives us a prior probability of mosaicism, independent of sequencing 
depth or variant caller, and allows us to calculate for each variant the posterior odds that a given 
site is mosaic rather than germline. To control for false discovery among our predicted mosaic 




1.4.6 Mosaic mutation detection model 
  To distinguish variant sites that show evidence of mosaicism from germline heterozygous 
sites, we modeled the number of reads supporting the variant allele (Nalt) as a function of the 
total variant position read depth (N). In the typical case, Nalt follows a Binomial distribution with 
parameters N (site depth) and p (mean VAF). However, we observed notable overdispersion in 
the distribution of variant allele fraction compared to the expectations under this Binomial model 
(>Fig. 1.16). To account for this overdispersion, we instead modeled Nalt using a Beta-Binomial 
distribution {Heinrich 2012; Ramu 2013}. We estimated an overdispersion parameter θ for our 
model as follows: for site depth values N in the range 1 to 500, we (1) bin variants by identifying 
all sites with depth N, (2) calculate a maximum-likelihood estimate θ value using N and all Nalt 
values observed for variants in a given bin, and (3) estimate a global θ value by taking the 
average of θ values across all bins, weighted by the number of variants in each bin. We then used 
θ in our Expectation-Maximization approach to jointly estimate prior mosaic fraction and to 
calculate per-site likelihood ratios. 
  To calculate the posterior odds that a given variant arose post-zygotically, we first 
calculated a likelihood ratio (LR) of two models: M0: germline heterozygous variant, and M1: 
mosaic variant. Under our null model M0, we calculated the probability of observing Nalt from a 
Beta-Binomial distribution with site depth N, observed mean germline VAF p, and 
overdispersion parameter θ. Under our alternate model M1, we calculated the probability of 
observing Nalt from a Beta-Binomial distribution with site depth N, observed site VAF p=Nalt/N, 
and overdispersion parameter θ. Finally, for each variant, we calculated LR by using the ratio of 
probabilities under each model and posterior odds by multiplying LR by our E-M estimated prior 
mosaic fraction estimate. We defined mosaic sites as those with posterior odds greater than 10 
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(corresponding to 9.1% FDR). We used posterior odds in this context to be able to control for 
false discovery, but we output similarly valid p-value and likelihood ratio scores for each de 
novo SNV.   
 
Figure 1.16. Overdispersion.  
Overdispersion is commonly seen in WES data {Heinrich 2012; Ramu 2013} and is defined as observing variance 
(in terms of (A) Nalt or (B) VAF of variants with a given DP value) higher than expected across DP values, under a 
given statistical model. The blue line denotes the expectation under a Binomial model and the red line denotes the 
expectation under a Beta-Binomial model. 
 
1.4.7 Simulation experiment 
Variant datasets used in the simulation experiment were generated as follows: 
For a given sample average sequencing depth value S, 
1) Generate n > 1,000,000 VAF values where VAF ~ Beta(=0.8, =7) / 2 
2) Generate n variant position read depth values (N) where N ~ NegativeBinomial(θ=4, 
mean=S) 
3) Generate n variant alternate allele read depth values (Nalt) where Nalt = VAF * N and 
recalculate VAF = Nalt / N 
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4) Apply FDR-based minimum Nalt threshold (used to control false positives during 
variant calling), removing ~90% of variants and leaving ~100,000 mosaics 
5) Apply the same procedure to generate 10 * n germline variants 
6) Combine mosaic variants with germline variants to produce final dataset 
7) Calculate true mosaic fraction  
 
To evaluate method performance on each dataset, we first estimated the false discovery 
rate (FDR) for each variant as a function of posterior odds (1/(1+posterior odds)).  Then, for 





  as well as the 
False Discovery Proportion (FDPj ; the fraction of variants with a ground truth label of 
“germline”) using the N variants with FDR < j before comparing the results.  Results are shown 





Figure 1.17. Simulation experiment results for 40x, 60x, 100x.  
Panel order from left to right correspond to 40x, 60x, 100x, respectively.  (A) Simulated variant datasets with a 
known true fraction of spiked in mosaic variants. (B) EM-estimated mosaic fraction compared to true mosaic 
fraction. (C) q-value vs. FDPtruth plots.  
 
1.4.8 Mutation confirmation by MiSeq amplicon sequencing 
  Chromosome coordinates were expanded 500 bp upstream and downstream of the 
candidate mosaic variants in the UCSC Genome Browser. Primer 3 Plus software was used to 
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design forward and reverse primers to generate 150-300 bp amplimers containing the candidate 
site. PCR reactions consisting of genomic DNA, primers, and Phusion polymerase were 
amplified by thermal cycling and purified with AMPure XP beads. The purified PCR product 
was quantified, and 0.5-1.0 ng of product was used to construct Nextera XT libraries according 
to the protocol published by Illumina. Libraries were purified using AMPure XP beads, and final 
libraries were quantified and pooled to undergo sequencing through Illumina MiSeq. 
We experimentally tested for the presence our predicted post-zygotic sites in the original 
blood DNA and cardiovascular tissue DNA samples using Illumina MiSeq Amplicon 
sequencing. The Amplicon Deep Sequencing workflow, optimized for the detection of somatic 
mutations in tumor samples, offers ultra-high sequencing depth (>1000x) that gives us the 
resolution to confirm low VAF variants, accurately estimate site VAF, and to distinguish true 
variant calls from technical artifacts. Mosaic candidates were considered validated if the variant 
allele matched the MiSeq call and both the mosaic VAF and MiSeq VAF indicated post-zygotic 
origin (VAF<0.45). 
Mosaic candidates were selected for confirmation on the basis of VAF, plausible 
involvement in CHD (based on predicted pathogenicity and HHE status), and detection method 
(Table S11; Table S12).  We sampled mosaics from both ends of the VAF spectrum to evaluate 
our ability to distinguish high VAF mosaics (VAF>0.2; n=29) from germline variants and to 
distinguish low VAF mosaics (VAF<=0.1; n=52) from technical artifacts.  Confirmation rate 
across different VAF bins is shown in >Figure 1.18.  We also selected for confirmation mosaics 
detected uniquely by either EM-mosaic or MosaicHunter, for the sake of method comparison 
(Table 1).   
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To examine a potential source of bias in our candidate selection process, we compared 
the posterior odds distribution of selected candidate mosaics (n=97) against those not chosen 
(n=212). We found that our tested candidates had lower posterior odds than untested mosaics 
(meantested=5.382, meanuntested=7.050, log10-scale; Mann Whitney U P=0.002) (>Fig 1.19), 
suggesting that our validation rate is not buoyed by testing variants with the strongest evidence 
of mosaicism.  For method development purposes, we intentionally focused on mosaics with 
lower posterior odds as these variants fall in the VAF range for which it is most difficult to 





Figure 1.18. Confirmation rate across VAF bins.  
The number of candidates for which we performed MiSeq resequencing among (A) the union set (n=143 tested) (B) 
all EM-mosaic calls (n=97) and (C) all MosaicHunter (n=68) calls vs. the number confirmed as mosaic for VAF 





Figure 1.19. Posterior odds comparison for tested vs. untested mosaics.  
Among 309 candidates with EM-mosaic posterior odds scores available, we compared the distribution of tested 
(n=97) vs. untested (n=212) mosaics.  The log10-scaled posterior odds distribution for the tested group is shown in 
blue (mean=5.382).  The log10-scaled mean posterior odds for the untested group is shown in red 
 
1.4.9 Investigating the relationship between VAF and pathogenicity 
  We hypothesized that mosaic contribution to disease is positively correlated with cellular 
percentage and by extension mutational timing. Here, we used variant allele fraction as a proxy 
for cellular percentage. We grouped mosaics into likely-damaging and likely-benign and 
compared the distribution of allele fraction in CHD-related genes. We defined likely-damaging 
variants as: (a) likely gene-disrupting (LOF) variants (including premature stop-gain, 
frameshifting, and variants located in canonical splice sites), (b) missense variants predicted to 
be damaging by REVEL {Ioannidis 2016} (with score ≥ 0.5) or (c) missense variants and 




























findings from previous CHD studies is that damaging de novo variants in genes highly expressed 
in the developing heart (“HHE”, ranked in the top 25% by cardiac expression data in mouse at 
E14.5 {Zaidi 2013; Homsy 2015}) contribute to non-isolated CHD cases that have additional 
congenital anomalies or neurodevelopmental disorders. Therefore, we considered the union of 
HHE genes and known candidate CHD genes {Jin 2017} as CHD-related genes (n=4558). For 
mosaics in CHD-related genes and for mosaics in other genes, we used a Mann-Whitney U Test 
to compare the VAF distributions of likely-damaging and likely-benign groups. 
 
1.4.10 Estimated contribution of mosaicism to CHD 
  We identified likely disease-causing mosaic mutations on the basis of predicted 
pathogenicity and presence in genes involved in biological processes relevant to CHD or 
developmental disorders. Each mosaic mutation was annotated with gene-specific information, 
including heart expression percentile, probability of loss-of-function intolerance (pLI) score 
{Lek 2016}, whether dysregulation causes CHD in mice {Smith 2018; Finger 2017}, and gene 
function {NCBI RefSeq}. We focused on HHE genes, genes with high pLI (pLI>0.9), genes that 
cause CHD phenotypes in mice, and genes involved in key developmental processes such as 
Wnt, mTOR, and TGF-beta signaling pathways. Then, for each patient, we used the clinical 
phenotype to further prioritize mosaic mutations most likely contributing to that individual’s 
clinical features. Detailed mutation annotation and clinical phenotypes for the mosaic carriers 
described above can be found in Table S10. We estimate the contribution of mosaicism to CHD 
as the percentage of individuals carrying likely disease-causing mosaic mutations among all 




1.4.11 Union with validated de novo SNVs from Jin et al. Nature Genetics 2017 
  As part of the PCGC program, Jin et al. previously sequenced and processed a cohort of 
2871 CHD probands – including 2530 parent-offspring trios used in this study – to investigate 
the contribution of rare inherited and de novo variants to CHD. They called a total of 2992 
proband de novo variants, including 2872 SNVs and 118 indels, and Sanger confirmed a subset 
of the most likely-disease causing variants. Since we processed the same proband-parent trios 
using different variant calling pipelines, we combined the results of our two approaches to 
provide a more complete input de novo call set for mosaic variant detection.  
  We first processed our SAMtools de novo calls using our upstream filters (n=2396 sites 
passing all filters). We then applied the same upstream filters to the published dnSNVs from Jin 
et al. (n=2650 sites passing all filters) before finally taking the union of these two call sets 
(n=3192). There were 1814 sites in the intersection, with 836 sites unique to the Jin et al. calls 
and 542 sites unique to our SAMtools calls. After preprocessing, outlier removal, and FDR-
based minimum Nalt filtering, the remaining 2971 dnSNVs were used as input to our mosaic 
detection model. 
  
1.4.12 Mutation spectrum analysis 
  We compared the mutation spectrum – the frequencies of all possible base changes – of 
our predicted mosaic candidates against the spectrum of our predicted germline heterozygous 
variants. Under the assumption that that post-zygotic events occur randomly (i.e. due to errors in 
DNA replication rather than a specific biological process), the mosaic mutation spectrum should 
not differ significantly from the germline mutation spectrum. We used Pearson’s Chi-square Test 
to test for a difference in frequencies across all base changes between our predicted sets of 
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variants. We interpreted large qualitative differences in base change frequencies as evidence of 
technical artifacts and rejection of the Chi-square null as evidence of systemic issues in our 
pipeline.  
  
1.4.13 Mosaic detection power given sample average coverage 
  To model statistical power in the context of mosaic variant detection, we considered two 
conditional probabilities: (i) the probability of detecting a mosaic event (i.e. the probability of a 
variant’s posterior odds exceeding a threshold) given site depth N, VAF, and overdispersion 
parameter θ and (ii) the probability of observing site depth N, given sample-wide average 
coverage DPsample.  
(i) Pr(detect mosaic | N, VAF, θ) was calculated by first identifying the VAF range (and 
by extension, the range of Nalt) over which posterior odds > cutoff, then by integrating the Beta-
Binomial probability mass function over this range, with considerations for the probability of 
strand bias (P(strand bias | N) ~ Binomial(Nalt, N, p=0.5)).  
(ii) Pr(observe N | DPsample) follows an overdispersed Poisson distribution that we 
approximated using a negative binomial model with overdispersion parameter θ {Sampson 
2011}. For each N value, we calculated a vector of weights corresponding to Pr(N | DPsample) for 
N values in the range (1, 1500).  
Finally, we took the sum of the detection probabilities described in (i) multiplied by the 
weights described in (ii) to determine the probability of detecting a mosaic variant given a 
sample average coverage value – Pr(detect mosaic | N). Our estimated detection power curves for 
a range of sample average coverage values typical of exome-sequencing studies are shown in 
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(>Fig. 1.2C). Our CHD cohort was sequenced to sample average depth of 60x, with prior mosaic 
fraction=0.121 and estimated θ=116.  
To estimate the true rate of mosaicism per exome given sample average coverage, we 
first split our set of predicted mosaics into VAF bins of size 0.05. For each bin above VAF 0.1, 
we multiplied the number of mosaics by the inverse of the detection power for that given VAF 
bin to estimate the true count of mosaic variants in that VAF range, assuming full detection 
power. Since EM-mosaic is underpowered to detect mosaics with VAF < 0.1 in the blood and 
since this range is enriched for technical artifacts that potentially affect our counts, we did not 
apply this scaling procedure to these bins to avoid over-inflating our adjusted mosaic rate 
estimate (>Fig. 1.7A). 
  
1.4.14 Filtering of MosaicHunter candidate variants  
MosaicHunter was used to identify candidate mosaic variants from blood exome-
sequencing trio data using default settings {Huang 2014}. Filtering of original MosaicHunter 
candidate variants excluded, in order, any variant present in ExAC (n=46634), G to T mutations 
with fewer than Nalt<10 oxidative indicating DNA damage {Costello 2013} (n=3995), non-
uniquely called sites (n=4719), germline SNVs previously called by GATK HaplotypeCaller 
(n=591), probands with >20 mosaic variants (n=1490 in 10 probands), mosaic log posterior 
likelihood ratio <10 (n=940), variants with >2 parental alternative allele reads (n=244), variants 




1.4.15 Filtering of MosaicHunter-detected cardiovascular tissue candidate variants 
  We used the MosaicHunter pipeline in trio mode to identify candidate variants in WES 
data from 70 cardiovascular tissue samples (belonging to 66 unique probands). From the list of 
variants initially reported by the pipeline using default settings, we applied the same filtration 
steps listed for MosaicHunter candidate variants in blood samples with the exception of the 
removal of G to T mutations with fewer than 10 alternative allele reads and the mosaic log 
posterior likelihood ratio <10. Finally, we removed variants that were identified in either parent 
or had a total read depth <10 in either parent. 
  
1.4.16 Clinical interpretation of mosaic variants – limitations 
We note that conventional clinical interpretation of mosaic mutations is challenging for 
several reasons: (i) it is unclear in which tissues each mosaic mutation is expressed (ii) several 
study participants were very young at time of clinical assessment and many classical disease 
features may not yet have developed or been noted, and (iii) the absence of additional clinical 
features does not necessarily rule out a mosaic mutation as being for the cause of the CHD. For 
the purposes of this study, we selected these mosaic mutations on the basis of predicted 
pathogenicity and detection in genes involved in biological processes relevant to CHD or 








Chapter 2: Genetic factors associated with clinical outcomes in CHD 
In this section, I discuss the development of an analytical framework to investigate the 
association between rare genetic variation and clinical outcomes in congenital heart disease 
patients (CHD).  Rare de novo, transmitted, and copy number variants were called from a cohort 
of 3966 CHD proband-parent trios.  We show that damaging de novo variants (DNVs) are 
associated with neurodevelopmental disorders (NDD) in CHD patients and that the enrichment is 
stronger when focusing on variants in genes highly expressed in developing hearts (HHE), 
known NDD risk genes, and genes that are both HHE and NDD-risk.  The prevalence of NDD is 
higher in CHD patients carrying likely pathogenic (LP) variants than in cases that do not 
carrying LP variants and the difference increases when focusing on variants in the gene sets of 
interest above.  Despite comprising roughly half of NDD-risk genes and only 5% of HHE genes, 
the genes that are annotated as both HHE and NDD-risk appear to drive the majority of the 
association and suggest that disruptive mutations in these genes have pleiotropic effects that 
likely play a role in the acquisition of NDD in our CHD patients.  We next focused on CHD 
patients diagnosed with single ventricle defects and found that damaging DNVs are enriched in 
patients with abnormal ventricular function phenotypes (decreased systemic ventricular function, 
worsening ventricular function, arrhythmia).  The enrichment is increases when considering 
variants in HHE genes, constrained genes (pLI>0.5), and genes that are both HHE and 
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constrained.   The prevalence of abnormal phenotypes is higher in CHD patients carrying likely 
pathogenic (LP) variants than in cases that do not carrying LP variants and the difference again 
increases when focusing on variants in the gene sets of interest above.  Genes that are annotated 
as both HHE and constrained comprise 57% of HHE genes and 42% of constrained genes and 
drive the majority of the association, suggesting pleiotropic effects of disruptive mutations in 
these genes.  Finally, we created a proof-of-concept rare variant risk score model to predict NDD 
on a per-patient basis by combining counts of rare de novo, transmitted, and copy number 
variants with weights defined by the strength of association with NDD for each particular gene 
set.  Our risk score achieved a 10-fold cross validated AUPRC of 0.44 when applied to all cases 
and AUPRCs of 0.32, 0.53, 0.46 when applied to cases with Isolated, Complex, and Unknown 
CHD subtypes, respectively.  We found that prevalence of NDD increased as function of risk 
score percentile and that patients with scores in the top 25% were 3.71-fold as likely to have 
NDD than patients in the bottom 25%, demonstrating that our score is able to stratify patients in 
a clinically meaningful way and identify patients at increased risk of NDD. 
 
2.1 Introduction 
Congenital heart disease (CHD) patients often acquire cardiac and non-cardiac 
comorbidities that impact quality of life, such as arrhythmias, myocardial dysfunctions, and 
neurodevelopmental disorders (NDDs) {Marino 2012; Calderon 2014; Miller 2005; Burnham 
2010}.  While these clinical outcomes have been associated with a variety of fetal 
developmental, surgical/post-operative, and genetic factors {Marelli 2016}, thus far none have 
been identified as the primary contributor {Zaidi 2017} and early identification of patients at risk 
for these poor outcomes remains a challenge. 
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CHD patients, especially those with single ventricle defects such as hypoplastic left heart 
syndrome or tricuspid atresia, often experience a range of poor outcomes following surgery that 
last into adulthood, including impaired systemic ventricular function, arrhythmias, and 
neurodevelopmental disorders {Feinstein 2012}.  Arrhythmias in particular may surface later in 
life and in conjunction with co-existing hemodynamic alterations are a common cause of 
mortality in adult congenital heart disease patients {Kairy 2006; Kanter 1997}.  Identification of 
CHD patients most at risk of developing these poor cardiac outcomes creates opportunities for 
improved care strategies and earlier therapeutic intervention.   
Among non-cardiac comorbidities, neurodevelopmental disorders (NDD) affect a 
disproportionately high number of CHD patients and have the largest impact on quality of life 
{Zaidi 2017}.  Neurodevelopmental disorders describe a spectrum of conditions including but 
not limited to intellectual disability, autism spectrum, and other cognitive, motor, social, and 
language deficits {Homsy 2015}.  Risk of acquiring NDD in CHD patients is a function of CHD 
severity/complexity and prevalence estimates range from 10% to over 50%, compared to 4-6% in 
the general population {Zaidi 2017; Homsy 2015; Marino 2012; Dixon-Salazar 2012}.  Both 
CHD and NDD impair reproductive fitness and tend to occur sporadically in individuals with no 
prior family history, pointing to strong contribution from de novo genetic variation.  Recent 
large-scale genetic studies in CHD {Zaidi 2013; Homsy 2015} and NDD cohorts {De Rubeis 
2014} have implicated disruption of chromatin modifying genes in both conditions, suggesting 
shared genetic etiology.  Further, CHD patients presenting with extracardiac anomalies, NDD, or 
both were found to be more likely to carry damaging de novo variants {Homsy 2015}.  Given 
disease heterogeneity and difficulty in resolving diagnosis criteria in infants, predicting risk of 
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acquiring NDD in CHD patients using genetic information presents an exciting clinical 
opportunity. 
Genetic disease risk is a combination of rare variants of large effect size and common 
variants of small effect sizes (and to varying degrees, environmental factors).  The Common 
Disease/Common Variants hypothesis {Reich 2001} posits that common variants drive risk of 
common disease and, by extension, that rare variants drive risk of rare disease.  Identification of 
individuals at high risk of acquiring specific diseases enables earlier therapeutic intervention and 
changes in patient management {Khera 2018}. Polygenic risk scores (PRS) aim to stratify 
patients and identify individuals at clinically significant increased risk by integrating the 
contribution of a large number of loci genome-wide. Introduced in 2010 {Ripatti 2010}, PRS 
have begun to gain traction as patient study cohorts have dramatically increased in size.  Using 
data from ~500,000 participants recruited as part of the recently released UK Biobank database, 
Khera and Kathiresan et al. developed a PRS that was able to identify 57,115 (19.8%) of 
participants in their testing dataset (n=288,978) at >3-fold risk of coronary artery disease, atrial 
fibrillation, type 2 diabetes, inflammatory bowel disease, and breast cancer {Khera 2018}.  
Scores have also been developed for a range of other common traits including but not limited to 
height, body mass index, and total cholesterol {Chatterjee 2013}, though the authors note that 
clinical utility of PRS depends on factors such as association study sample size and genetic 
architecture.  Given that rare genetic variation typically contributes larger effect size, the field 
has also seen the development of a genome-wide rare variant risk score for schizophrenia 
{Purcell 2014} and a genome-wide de novo risk score for autism spectrum disorder {An 2018}, 
highlighting considerable interest in patient risk stratification on the basis of genetic variation.  
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Currently no risk score exists for predicting NDD risk in CHD, which we believe is an unmet 
need with significant clinical utility. 
 
2.2 Results  
2.2.1 Complex CHD cases are more likely to acquire NDD than Isolated CHD cases 
 Our cohort of 3966 CHD cases was annotated with information about extracardiac 
anomalies and NDD diagnosis and stratified along these two axes (>Table 2.1). Here, Complex 
cases were defined as having at least one other extracardiac anomaly (e.g. Skeletal, Craniofacial, 
Genitourinary, etc), Isolated cases were defined as having no extracardiac anomalies, with 
Unknown indicating cases where this information was not available.  NDD cases were defined as 
having received services for cognitive, motor, social, or language impairments, non-NDD 
defined as not having received the services above, with Unknown NDD describing patients with 
unclear diagnosis (typically patients <1 year old at evaluation).  Recent genetic and clinical 
studies have established a relationship between increased CHD complexity and increased 
prevalence of NDD {Homsy 2015; Marino 2012}. As a sanity check, we compared the relative 
numbers of NDD and non-NDD cases among our CHD patients with Complex and Isolated 
presentations to see if we could reproduce this finding.  Among 565 patients with Complex CHD 
and a definitive NDD diagnosis, 240 were annotated as having NDD and 325 were non-NDD 
cases.  Among 1175 patients with Isolated CHD, 305 were annotated as having NDD and 870 
were non-NDD cases.  We found that cases with Complex CHD were more likely to acquire 













All NDD* Non-NDD 
Unknown 
NDD** 
All 3966 652 1588 1726 
Isolated 1803 305 870 628 
Complex 996 240 325 431 
Unknown 1167 107 393 667 
 
2.2.2 Damaging de novo variants are associated with NDD 
 We called a total of 5271 de novo variants (DNVs) from our cohort of 3966 CHD cases.  
We then compared counts of variants per individual across different classes of functional 
consequence (>Table 2.2).  Excluding cases with an unknown NDD diagnosis, we found that 
likely gene-disrupting (LGD) DNVs are enriched in cases with NDD (Relative Risk (RR)=1.59, 
p=3e-05, Binomial Test).  This enrichment is stronger when considering only LGD DNVs 
located in genes highly expressed in developing heart (HHE; RR=2.38, p=8e-08) and genes that 
are known NDD risk genes (RR=8.43, p=3e-14).  Interestingly, the signal further increases when 
focusing on the variants located in genes that are at the intersection of HHE and NDD-risk genes 
(RR=9.26, p=1e-12).  We see a similar trend when grouping LGD and Dmis variants (>Fig. 2.1). 
We observed a depletion of synonymous DNVs in NDD cases (RR=0.87, p=0.12) and we 
believe this to be due to technical differences (average depth and uniformity between batches of 
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patients sequenced at different times with different capture kits) rather than biological 
differences (>Fig. 2.7). 
 We next compared the prevalence of cases with NDD and the prevalence of cases without 
NDD among patients carrying likely pathogenic (LP; LGD + Dmis) DNVs and those that do not.  
We found that the prevalence of NDD is higher among patients carrying LP DNVs (21% NDDLP 
vs. 14% NDDnonLP) and that the NDD prevalence increases when considering only LP variants in 
HHE genes (26% NDD), NDD risk genes (41% NDD), and genes that are both HHE and NDD-
risk (45%) (>Fig. 2.2, Table 2.3).  The difference in prevalence (NDDLP – NDDnonLP) also 
follows the same trend, with difference values of 7%, 11%, 26%, and 29% for All, HHE, NDD-
risk, and HHE&NDD-risk gene sets, respectively. 
 

















#NDD = 652 
#non = 1588 
#unk = 1726  
All 
LGD 0.21 0.14 0.08 1.59 3.1E-05 
Dmis 0.23 0.17 0.06 1.35 0.004 
HHE 
LGD 0.12 0.05 0.07 2.38 7.9E-08 
Dmis 0.11 0.06 0.05 1.73 5.0E-04 
NDD-
risk 
LGD 0.07 0.01 0.06 8.43 3.1E-14 




LGD 0.06 0.01 0.05 9.26 1.0E-12 
Dmis 0.03 0.01 0.02 3.37 0.001 
LGD=likely-gene-disrupting, Dmis=deleterious missense, NDD=neurodevelopmental disorder, non=non-NDD, 







Figure 20. Damaging (LGD + Dmis) DNVs are enriched across gene sets.   
We observe an enrichment across All genes, HHE, and NDD-risk genes across all CHD subtypes (Isolated, 
Complex, Unknown).  The strongest enrichment is observed in genes that are annotated as both HHE and NDD-risk.  
HHE=high heart expression, NDD=neurodevelopmental disorder, NDD risk=known NDD risk genes, 




Figure 21. Higher prevalence of NDD among cases carrying likely pathogenic DNVs.  
(A) DNVs in all genes.  (B) DNVs in HHE genes. (C) DNVs in NDD-risk genes. (D) DNVs in genes annotated as 
both HHE and NDD-risk genes. The difference in NDD prevalence between LP and nonLP cases increases when 
considering DNVs in either HHE or NDD-risk genes, with the largest difference observed when considering DNVs 
in genes at the intersection of HHE and NDD-risk gene sets.  The largest difference is observed in Complex CHD 
cases and is consistent across gene groups.  For Isolated CHD cases, however, the difference is most noticeable in 
NDD-risk genes and genes at the intersection of HHE and NDD-risk. LP=cases carrying likely pathogenic DNVs, 
nonLP=cases that do not carry likely pathogenic DNVs, HHE=high heart expression, NDD=neurodevelopmental 
disorder.  Stars indicate statistical significance: NS=non-significant, ‘*’=p<0.05, ‘**’=p<0.01, ‘***’=p<0.001, 
Fisher’s Exact Test. 
 























OR P-value sig 
All All 245 904 407 2410 0.21 0.14 0.07 1.60 2.4E-07 *** 
All Isolated 93 387 212 1111 0.19 0.16 0.03 1.26 0.10 NS 
All Complex 112 228 128 528 0.33 0.20 0.13 2.02 3.8E-06 *** 
All Unknown 40 289 67 771 0.12 0.08 0.04 1.59 0.03 * 
HHE All 140 407 512 2907 0.26 0.15 0.11 1.95 3.9E-09 *** 
HHE Isolated 47 170 258 1328 0.22 0.16 0.05 1.42 0.05 NS 
HHE Complex 76 127 164 629 0.37 0.21 0.17 2.29 1.5E-06 *** 
HHE Unknown 17 110 90 950 0.13 0.09 0.05 1.63 0.10 NS 
NDD-risk All 70 101 582 3213 0.41 0.15 0.26 3.82 4.8E-15 *** 
NDD-risk Isolated 18 33 287 1465 0.35 0.16 0.19 2.78 0.001 ** 
NDD-risk Complex 40 41 200 715 0.49 0.22 0.28 3.48 2.3E-07 *** 
NDD-risk Unknown 12 27 95 1033 0.31 0.08 0.22 4.82 9.1E-05 *** 
HHE & 
NDD-risk 
All 56 69 596 3245 0.45 0.16 0.29 4.42 3.2E-14 *** 
HHE & 
NDD-risk 
Isolated 12 22 293 1476 0.35 0.17 0.19 2.75 0.01 ** 
HHE & 
NDD-risk 
Complex 33 32 207 724 0.51 0.22 0.29 3.60 1.5E-06 *** 
HHE & 
NDD-risk 
Unknown 11 15 96 1045 0.42 0.08 0.34 7.95 5.6E-06 *** 
LP=cases carrying likely pathogenic DNVs, nonLP=cases that do not carry likely pathogenic DNVs, HHE=high 
heart expression, NDD=neurodevelopmental disorder, NDD-risk=known NDD risk genes. 
 
2.2.3 Mutations with pleiotropic effects drive the acquisition of NDD in CHD 
There are 4420 genes that are highly expressed in the developing mouse heart (HHE) and 
539 known NDD risk genes.  The 261 genes annotated as both HHE and NDD-risk comprise 
about half of NDD-risk genes and only about 5% of HHE genes (>Fig. 2.3A), yet the LGD 
DNVs located in this subset of genes show the strongest association with NDD in our CHD 
cohort (RR=9.26, p=1e-12) (>Table 2.2).  If we use the difference in rates of DNVs in NDD 
cases and non-NDD cases as a proxy for population attributable risk (PAR), we observe a PAR 
of 8% when we consider LGD DNVs in all genes, a PAR of 7% for LGD DNVs in HHE genes, 
and a PAR of 6% for DNVs in NDD risk genes.  The PAR of 5% for LGD DNVs in genes that 
are both HHE and NDD-risk represents a substantial fraction of the overall PAR and suggests 
again that these genes are most strongly associated with NDD (>Fig. 2.3B).  Though less 
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striking, we observe a similar trend when considering Dmis DNVs (>Fig. 2.3C).  Given the gene 
set size and relative PAR, we hypothesize that mutations disrupting these specific genes have 
pleiotropic effects that play a role in the acquisition of NDD in CHD.   
 
Figure 22. Genes annotated as both HHE & NDD-risk contribute substantial PAR and suggest 
pleiotropic activity.   
Despite comprising roughly half of NDD-risk genes and ~5% of HHE genes, the genes at the intersection show the 
strongest association with NDD and contribute a substantial fraction of the PAR.  The trend is most noticeable when 
considering LGD DNVs but also seen to a lesser degree in Dmis DNVs.  PAR=population attributable risk, 
HHE=high heart expression, NDD=neurodevelopmental disorder, NDD-risk=known NDD risk genes, LGD=likely-
gene-disrupting, Dmis=deleterious missense.   
 
2.2.4 Damaging de novo variants are associated with abnormal ventricular function in 
patients with single ventricle defects   
We next focused on the 114 CHD cases seen at Columbia University Medical Center who 
were diagnosed with single ventricle defects and analyzed the 654 de novo variants belonging to 






























Worsening Ventricular Function, and Arrhythmia as our clinical outcome variable and repeated 
the analyses above (>Table 2.4).  We found that damaging DNVs were associated with 
Decreased Systemic Ventricular Function (RR=2.72, p=0.01) and that this association increased 
when focusing on constrained genes (pLI) (RR=3.63, p=0.02), HHE genes (RR=4.49, p=0.01), 
and genes that are annotated as both HHE and pLI (RR=5.18, p=0.02).  We observed a similar 
trend in the association between damaging DNVs and Worsening Ventricular function between 
all genes (RR=2.11, p=0.05), HHE genes (RR=3.78, p=0.02), pLI (RR=4.47, p=0.003), and 
genes that are both HHE and pLI (RR=8.59, p=0.001).  We also see a similar trend in 
Arrhythmia for damaging DNVs in all genes (RR=2.31, p=0.08), HHE genes (RR=2.52, p=0.11), 
pLI genes (RR=3.46, p=0.05), and HHE&pLI genes (RR=3.46, p=0.05).   
We next compared the prevalence of cases with the phenotypes described above among 
patients carrying likely pathogenic DNVs and those that do not (>Fig. 2.4; Table 2.5).  We did 
not stratify CHD cases into Isolated and Complex due to sample size constraints.  We found that 
the Decreased Systemic Ventricular Function phenotype prevalence is higher among patients 
carrying LP DNVs (73% LP vs. 42% nonLP; OR=3.72, p=0.007, Fisher’s Exact Test) and that 
the phenotype prevalence increases when considering only LP variants in constrained (pLI) 
genes (76%), HHE genes (80%), and genes that are both HHE and pLI (82%).  The difference in 
prevalence (% in LP – % in nonLP) also follows the same trend, with difference values of 31%, 
32%, 36%, and 46% for All, pLI (OR=4.05, p=0.02), HHE (OR=4.96, p=0.01), and HHE&pLI 
(OR=5.31, p=0.03) gene sets, respectively.  The findings are similar for the Worsening 
Ventricular Function phenotype – 58% in LP vs. 30% in nonLP cases (OR=3.14, p=0.02) – 
though the trend shows both a higher phenotype prevalence and a larger difference in phenotype 
prevalence between LP and nonLP carriers in the constrained genes (71% LP vs. 30% nonLP; 
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OR=5.41, p=0.002) compared HHE genes (67% LP vs. 32% nonLP; OR=4.2, p=0.02) 
suggesting that the relative contributions of genes in these two gene sets differs by phenotype.  
The HHE&pLI gene set again shows the strongest signal (82% LP vs. 32% nonLP; OR=9.53, 
p=0.002).  The Arrhythmia phenotype did not show as strong evidence of a trend as the others; 
the main difference in phenotype prevalence between LP carriers and nonLP carriers was limited 
to constrained genes (29% LP vs. 10% nonLP; OR=3.87, p=0.04). 
There are 4420 genes that are highly expressed in the developing mouse heart (HHE) and 
6050 constrained genes (pLI).  The 2520 genes annotated as both HHE and pLI comprise 57% of 
HHE genes and 42% of pLI genes (>Fig. 2.5), yet the damaging DNVs located in this subset of 
genes show the strongest association with the three clinical outcomes described above. Given the 
gene set size and relative PAR across the different phenotypes (>Table 2.4), the mutations 
disrupting these specific genes again appear to have pleiotropic effects that play a role in the 
acquisition of abnormal ventricular function phenotypes in CHD patients diagnosed with single 
ventricle defects. While not reaching statistical significance, the results of this results of this 
section provide additional evidence for the pleiotropy hypothesis proposed in the previous 
sections; however, larger sample sizes will be necessary to draw strong conclusions about the 





Table 2.4. Rates of damaging DNVs among 114 patients with single ventricle defects with 
abnormal phenotypes.   





(n = 112) 
(55 yes, 57 no) 
All 0.38 0.14 0.24 2.72 0.01 
HHE 0.24 0.05 0.18 4.49 0.01 
pLI 0.25 0.07 0.18 3.63 0.02 




(n = 106) 
(39 yes, 67 no) 
All 0.41 0.19 0.22 2.11 0.05 
HHE 0.28 0.07 0.21 3.78 0.02 
pLI 0.33 0.07 0.26 4.47 0.003 
HHE & pLI 0.26 0.03 0.23 8.59 0.001 
Arrhythmia 
(n = 111) 
(14 yes, 97 no)  
All 0.50 0.22 0.28 2.31 0.08 
HHE 0.29 0.11 0.17 2.52 0.11 
pLI 0.43 0.12 0.30 3.46 0.02 
HHE & pLI 0.29 0.08 0.20 3.46 0.05 
DNV=de novo variant, damaging=LGD and Dmis DNVs, PAR=population attributable risk, HHE=high heart 




Figure 23. Higher abnormal phenotype prevalence among cases carrying likely pathogenic 
DNVs.  
(A) Prevalence of the Decreased Systemic Ventricular Function phenotype. The phenotype prevalence increases 
when considering constrained or HHE genes and is the largest in genes annotated as both. (B) Prevalence of the 
Worsening Ventricular Function phenotype. The phenotype prevalence shows a similar trend, except that 
constrained genes have higher prevalence than HHE genes.  Again, genes that are HHE&pLI show the highest 
phenotype prevalence(C) Prevalence of the Arrhythmia phenotype. LP=cases carrying likely pathogenic DNVs, 
nonLP=cases that do not carry likely pathogenic DNVs, HHE=high heart expression, pLI=constrained (pLI>0.5), 
sys_fx_abnormal=decreased systemic ventricular function, worsen_time=worsening ventricular function. Stars 




Table 2.5. Prevalence of NDD in cases carrying LP DNVs vs. cases that do not.   

























All 19 7 36 50 0.73 0.42 0.31 3.72 0.01 ** 
HHE 12 3 43 54 0.80 0.44 0.36 4.96 0.01 * 
pLI 13 4 42 53 0.76 0.44 0.32 4.05 0.02 * 




All 15 11 24 56 0.58 0.30 0.28 3.14 0.02 * 
HHE 10 5 29 62 0.67 0.32 0.35 4.21 0.02 * 
pLI 12 5 27 62 0.71 0.30 0.40 5.41 0.002 ** 
HHE&pLI 9 2 30 65 0.82 0.32 0.50 9.53 0.002 ** 
Arrhythmia 
All 6 19 8 78 0.24 0.09 0.15 3.04 0.08 NS 
HHE 3 11 11 86 0.21 0.11 0.10 2.11 0.38 NS 
pLI 5 12 9 85 0.29 0.10 0.20 3.87 0.04 * 
HHE&pLI 3 8 11 89 0.27 0.11 0.16 2.99 0.14 NS 
LP=cases carrying likely pathogenic DNVs, nonLP=cases that do not carry likely pathogenic DNVs, HHE=high 
heart expression genes, pLI=constrained (pLI>0.5) genes. 
 
 
2.2.5 Rare variant risk score predicts NDD in CHD patients 
 We developed a proof-of-concept rare variant risk score model to predict NDD on a per-
patient basis by combining counts of rare de novo, transmitted, and copy number variants with 
weights defined by the strength of association with NDD for each particular gene set.  For each 
variant type (de novo, transmitted, CNV), weights were estimated using the enrichment (RR) in 
NDD cases of each combination of functional class (LGD, Dmis, DEL, DUP) and gene set 
(genes annotated as both HHE and NDD-risk genes, CHD risk genes, genes annotated as HHE 
and/or constrained (pLI), and in all other genes) (>Tables 2.6, 2.7, 2.8).  The per-patient risk 
score was calculated as the sum of the log2-scaled weights across all variant-geneset 
combinations observed in the individual, given all rare variants detected for that individual. 
 We compared the score distribution between NDD cases and non-NDD cases and found 
that while many cases with lower scores overlapped between the two groups, cases with NDD 
tended to have higher risk scores and the mean risk score for NDD cases was higher than the 
mean risk score for non-NDD cases (NDD mean=1.38, non-NDD mean=0.75; p=1.1e-19, 
73 
 
Wilcoxon Rank-Sum Test) (>Fig. 2.5).  We observed the greatest separation in Unknown CHD 
cases (NDD mean=1.65, non-NDD mean=0.65; p=2.9e-06) and Complex CHD cases (NDD 
mean=2.29, non-NDD mean=1.68; p=1e-05) whereas we observed the least separation in 
Isolated CHD cases (NDD mean=0.63, non-NDD mean=0.47; p=0.001). We next evaluated the 
ability to discriminate between NDD and non-NDD cases using 10-fold cross validation.  Our 
risk score achieved a mean AUPRC of 0.44 (across folds) when applied to all cases and mean 
AUPRCs of 0.32, 0.53, 0.46 when applied to cases with Isolated, Complex, and Unknown CHD 
subtypes, respectively (>Fig. 2.6).  We believe the observed trends in score performance per 
group reflect the established relationship between CHD complexity and NDD and that our 
Unknown CHD group represent a mixture of Isolated and Complex cases.    
 
Figure 24. Risk score distribution in NDD vs. non-NDD cases, across CHD subtype groups.  
(A) All CHD cases. (B) Isolated cases. (C) Complex cases. (D) Unknown cases.  Higher risk score values showed 
the largest separation between NDD and non-NDD cases. The score distributions showed a larger difference in 
Complex and Unknown cases than in Isolated cases. NDD=neurodevelopmental disorder, wilcox.p=Wilcoxon Rank-






































































































A B C D
74 
 
Figure 25. Risk score performance, 10-fold cross validated Precision-Recall curves.  
 (A) All CHD cases. (B) Isolated cases. (C) Complex cases. (D) Unknown cases.  The score showed the strongest 
performance in discriminating NDD from non-NDD cases in Complex cases and showed the weakest performance 
in Isolated cases.  The performance in Unknown cases fell in between that in Complex and Isolated groups, likely 
due to the Unknown group containing a mixture of true Complex and Isolated presentations.  Iso=isolated, 
cmp=complex, unk=unknown, AUC=area under (precision-recall) curve. 
 
 
We next considered the prevalence and enrichment of NDD as a function of patient risk 
score percentile.  We found that the prevalence of NDD increased among patients with higher 
risk score percentiles (>Fig 2.7).  The increase in prevalence was greatest in cases with Complex 
CHD and least in cases with Isolated CHD, with Unknown CHD in the middle.  We also found 
that patients with risk scores in the top 25% were >3-fold as likely to have NDD (OR=3.71, 
p=8.1E-17, Fisher’s Exact Test) compared to patients in the bottom 25% (>Fig 2.8).  Again, the 
enrichment was greatest in Complex (OR=3.43, p=0.00003) and Unknown (OR=3.43, p=0.0005) 
CHD cases and least in Isolated CHD (OR=1.90, p=0.006).   
 
 
Figure 26. Prevalence of NDD as a function of risk score percentile  
(A) All CHD cases. (B) Isolated cases. (C) Complex cases. (D) Unknown cases.  The score increases most 
dramatically for Complex CHD cases, least dramatically for Isolated CHD cases.  Unknown CHD cases show 







Figure 27. Enrichment of NDD by risk score quartile, compared to bottom quartile 
(B) All CHD cases. (B) Isolated cases. (C) Complex cases. (D) Unknown cases.  Patients with risk scores in the top 
25% were >3-fold as likely to have NDD (OR=3.71, p=8.1E-17) compared to patients in the bottom 25%. 
Complex (OR=3.43, p=0.00003) and Unknown (OR=3.43, p=0.0005) CHD cases showed the largest 
enrichment while Isolated CHD (OR=1.90, p=0.006) cases showed the least. 
 
2.3 Discussion  
In this study, we conducted an association analysis between rare variants and clinical 
outcomes in 3966 CHD patients.  We found that damaging de novo variants are associated with 
NDD cases and that the association is stronger for variants in HHE genes or in NDD-risk genes, 
and strongest for variants in genes annotated as both HHE&NDD-risk.  We see a similar trend 
when comparing the relative prevalence of NDD in cases carrying likely pathogenic DNVs in 
each of the gene sets above.  The genes annotated as HHE&NDD-risk comprise roughly half of 
NDD-risk genes and ~5% of HHE genes yet appear to drive the association with NDD.  We 
believe this to suggests that disruptive mutations in these critical genes have pleiotropic effects 
that play a role in the acquisition of NDD in CHD patients. While we did not observe the same 
strength or significance of association with rare transmitted variants, we found that transmitted 
LGD variants in HHE genes had a PAR of 8% -- comparable with that observed in de novo 
variants and suggestive of an underlying association missed by the limited sample size in this 
analysis (>Table 2.7). CNVs overall were enriched in NDD cases (RR=2.09, p=7e-06), with 
deletion events appearing to drive the association (RR=3.00, p=1e-07) (>Table 2.8). However, 
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given the small number of CNVs detected, the generalizability of this association remains to be 
determined.   
Focusing on the 114 CHD patients diagnosed with single ventricle defects, we found a 
similar association between damaging DNVs and abnormal ventricular function phenotypes 
(Decreased Systemic Ventricular Function, Worsening Ventricular Function, Arrhythmia).  The 
association is stronger when considering damaging DNVs in HHE genes or in constrained genes 
and is strongest for damaging DNVs in genes annotated as both HHE and constrained, providing 
additional support for the pleiotropy hypothesis.  Damaging DNVs in HHE genes appear to be 
more strongly associated with the Decreased Systemic Ventricular Function phenotype whereas 
damaging DNVs in constrained genes show stronger association with Worsening Ventricular 
Function, potentially hinting at different mechanisms driving these respective phenotypes.   
Finally, we combined information from rare de novo, transmitted, and copy number 
variants into a proof-of-concept per-patient rare variant risk score.  The score distributions 
between NDD and non-NDD cases were more distinct for higher score values and for cases with 
Complex and Unknown CHD presentations.  Using 10-fold cross validation to evaluate the 
performance of our score in distinguishing NDD from non-NDD cases, we achieved an AUPRC 
of 0.44 for all cases and auPRC values of 0.32, 0.53, and 0.46 for Isolated, Complex, and 
Unknown cases, respectively.  Here, weights were derived by comparing NDD vs. non-NDD 
cases within our CHD cohort; estimates from a comparison of CHD-NDD cases vs. non-CHD 
non-NDD age and sex matched controls would likely provide more information and improve the 
overall discriminatory performance of our method, particularly in Isolated CHD cases.  
In conclusion, we found that genes annotated as both HHE and NDD-risk are most 
strongly associated with NDD in CHD and that disruptive de novo variants in these genes likely 
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have pleiotropic effects.  We also found that genes annotated as both HHE and constrained are 
most strongly associated with abnormal ventricular function phenotypes in CHD patients with 
single ventricle defects and that the disruptive de novo variants in these genes provide additional 
evidence of pleiotropy.  Our rare variant risk score shows potential in distinguishing CHD cases 
with NDD from non-NDD cases and represents a proof-of-concept application of genomic 
information in predicting clinical outcomes.  As study cohorts increase in size, we will soon be 
able to more accurately and robustly quantify the association between different classes of genetic 
variation and phenotypes of interest using the methods described here.  With improved measures 
and further development, we believe that genetic risk scores have the potential to provide 
clinically actionable information and guide the refinement of existing disease diagnosis and 
management strategies.  
 
2.4 Materials and Methods 
2.4.1 Sequencing data, variant calling, and quality control  
We analyzed data from 3966 congenital heart disease (CHD) proband-parent trios 
recruited as part of the Pediatric Cardiac Genomics Consortium (PCGC) study {Homsy 2015; Jin 
2017}. Genomic DNA from venous blood or saliva was captured using Nimblegen v.2 exome 
capture reagent (Roche) or Nimblegen SeqCap EZ MedExome Target Enrichment Kit (Roche) 
(for whole-exome sequencing datasets) followed by Illumina DNA sequencing (paired-end, 
2x75bp) {Jin 2017, Zaidi 2013}. Sequence reads were mapped to the hg19 human reference 
genome with BWA-MEM and BAM files were further processed following GATK Best 




Candidate de novo variants were defined as sites present in the offspring with 
homozygous reference genotypes in both parents.  Candidates satisfying any of the following 
criteria were filtered out and excluded from subsequent analysis: (1) failing VQSR filter (2) 
Fisher Strand (FS)>25 (2) Quality by Depth (QD)<2 (3) <5 reads supporting the alternate allele 
in proband (4) <20% alternate allele fraction in proband (5) Phred-scaled genotype likelihood 
(GQ) <60 (6) ExAC population allele frequency >0.1% (7) <10 reference reads in either parent 
(8) >5% alternate allele fraction in either parent or (9) GQ<30 in either parent.  There were in 
total 5271 de novo variants passing filters belonging to 3966 patients.  
Transmitted variants were extracted from the joint-genotype VCFs and defined as sites 
present in the offspring with at least one parent having a non-homozygous reference genotype.  
Candidates satisfying any of the following criteria were filtered out and excluded from 
subsequent analysis: (1) GQ<30 (2) average depth across interval (IDP) <=9 (3) <25% alternate 
allele fraction (4) gnomAD exome/genome population allele frequency >0.001% (5) Phred-
scaled p-value for exact test of excess heterozygosity (ExcessHet) >55 (6) DP<10 in proband (7) 
DP<10 in either parent or (8) non-European ethnicity.  There were in total 166100 rare 
transmitted variants passing filters belonging to 2618 patients of European (EUR) ethnicity. 
Copy number variants were called using PennCNV.  Samples with total # CNV calls >4 
standard deviations (SD) from the cohort mean were considered outliers and removed from 
subsequent analysis.  Candidates satisfying any of the following criteria were filtered out and 
excluded: (1) Log R Ratio (LRR) >0.35 SD from sample mean (2) B Allele Frequency (BAF) >4 
SD from sample mean (3) BAF drift >4 SD from mean (4) Wave factor <-0.03 or >0.03 (5) # 
SNPs <10 (6) CNV size <100kb (7) Confidence score <30 (8) >80% overlap with repetitive 
regions (9) AC in parents >2 (10) gnomAD population frequency >0.1% (11) >5 de novo large 
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CNVs per individual (13) not annotated as overlapping genes.  There were in total 237 CNVs 
passing filters belonging to 1794 patients for which array data was available. 
 
2.4.2 Depth of coverage and D15 for NDD and non-NDD samples across batches 
CHD samples were collected in 9 batches.  For quality control purposes, we calculated 
sample average depth (DP) and D15 values for each sample BAM file using the GATK 
DepthOfCoverage tool.  We then compared NDD cases and non-NDD cases to identify potential 
technical sources of bias in our downstream analysis.  We found that overall mean DP and D15 
were comparable between NDD and non-NDD cases (DPNDD=58.08, DPnonNDD=58.5, 
D15NDD=87.47, D15nonNDD=88.39).  However, we note that were fewer NDD cases with high 
D15 than non-NDD cases (>Fig. 2.9).   
 
Figure 28. Comparison of DP and D15 in NDD and non-NDD samples. 
Per-sample summary statistics were generated using the GATK DepthOfCoverage tool. (A) Sample average depth. 
(B) D15 (% of bases covered by >15 reads). (C) Sample average depth vs. D15. 
 
2.4.3 Annotations and gene sets 
Variants were annotated using both Ensembl Variant Effect Predictor (VEP) (release 96) 
and ANNOVAR (v2017-07-17) to include information from the dbNSFP version 4.0a database, 
as well as pathogenicity predictions from a variety of established methods (CADD, MCAP, 
NDD mean D15 87.47

























NDD mean DP 58.08
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































REVEL, MPC, MVP, MVP2, spliceAI).  We used defined likely-gene-disrupting (LGD) variants 
as stopgain, stoploss, frameshift, startloss, or spliceAI >0.5.  We defined deleterious missense 
(Dmis) variants as nonsynonymous sites with REVEL score >=0.5 and probably-deleterious-
missense (PDmis) variants as nonsynonymous sites with REVEL score <0.5 and CADD >=20.  
Splice-likely-pathogenic (spliceLP) variants were defined as variants with a spliceAI score 
between 0.2 and 0.5.  Benign missense (Bmis) variants were defined as nonsynonymous sites not 
in the groups above.  For synonymous variants and inframe-indels, we excluded sites with 
spliceAI score >0.2.  We considered sites predicted to be LGD or Dmis as damaging (likely 
pathogenic). Non-likely pathogenic sites include all variants not in the damaging group. 
Gene sets were defined as follows.  High Heart Expression (HHE) genes (n=4420) 
include those ranked in the top 25% by cardiac expression data in mouse at E14.5 {Zaidi 2013; 
Homsy 2015}.  CHD-risk genes (n=156) were defined as known candidate CHD genes with 
autosomal dominant mode of inheritance {Jin 2017}.  NDD-risk genes (n=539) were defined as 
the union of genes with SFARI score 1 or 2 (n=86), genes discovered by the Autism Sequencing 
Consortium (ASC) with FDR<0.1 (n=102) {Satterstrom 2019}, and genes in the Developmental 
Disorders Genotype-Phenotype (DDG2P) database with indicated organ ‘brain’ and with human 
phenotype ontology (HPO) terms ‘abnormal brain morphology’ (HP: 0012443) or ‘cognitive 
impairment’ (HP:0100543) (n=454).  Constrained/pLI genes (n=6050) were defined as genes 
with gnomAD pLI>0.5 {Lek 2016}.   
 
2.4.4 Association analysis  
 We used a Binomial Test and a Fisher’s Exact Test to investigate the association between 
genetic variation and clinical outcomes of interest. Patients were first divided into groups based 
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on phenotype (e.g. NDD, non-NDD, Decreased Systemic Ventricular Function, no Decreased 
Systemic Ventricular Function, etc).  Then, for each variant functional class (e.g. LGD, Dmis, 
Bmis, DEL, DUP, etc), we counted the number of variants detected in patients belonging to each 
phenotype group and calculated a per-group rate.  The enrichment (relative risk) was calculated 
as the ratio of the rates in the positive phenotype and corresponding negative phenotype groups.  
We also calculated the difference in rates between positive and negative phenotype groups as a 
proxy for population attributable risk (PAR).  To assess significance, we used a Binomial Test 
with the total number of variants detected across both groups as our number of trials (N), the 
proportion of cases with the positive phenotype among all patients in both groups as our null 
probability of success (p), and the number of variants detected in cases with the positive as our 
number of successes (x).  Since the number of variant counts varied between functional classes, 
we also used a Fisher’s Exact Test to improve association accuracy for classes with low counts.  
Patients were further divided into 4 subsets – cases with positive phenotype and carrying the 
variant, cases with negative phenotype and carrying the variant, cases with positive phenotype 
and not carrying the variant, and cases with negative phenotype and not carrying the variant.  We 
then tested for nonrandom association between phenotype and variant functional class variables.  
This analysis was repeated for each CHD subtype (All, Isolated, Complex, Unknown CHD), 
CHD category (conotruncal defect (CTD), heterotaxy (HTX), hypoplastic left heart syndrome 
(HLHS), left ventricular outflow (LVO), other), and gene set (All genes, HHE, constrained, 




2.4.5 Prevalence analysis 
 We used a Fisher’s Exact Test to investigate whether patients carrying likely pathogenic 
(LP; LGD + Dmis) variants were more likely to also have the clinical outcome of interest. 
Patients were first divided into two groups – cases carrying LP variants and cases that do not 
carry an LP variant.  We then counted the number of patients with the positive phenotype and the 
negative phenotype within each LP group and calculated a per-group phenotype prevalence and a 
prevalence difference value.  Using the number of cases carrying LP variants with the positive 
phenotype, cases carrying LP Variants with the negative phenotype, cases without LP variants 
with the positive phenotype, and cases without LP variants with the negative phenotype, we used 
a Fisher’s Exact Test to test for significance and strength of nonrandom association between 
phenotype and LP variant variables.  This analysis was repeated for each CHD subtype (All, 
Isolated, Complex, Unknown CHD), CHD category (conotruncal defect (CTD), heterotaxy 
(HTX), hypoplastic left heart syndrome (HLHS), left ventricular outflow (LVO), other), and 
gene set (All genes, HHE, constrained, CHD-risk, NDD-risk, and combinations of these).   
 
2.4.6 NDD rare variant risk score  
 We developed a simple framework for predicting clinical outcomes of interest (e.g. 
NDD) by combining information from rare de novo, transmitted, and copy number variants into a 
per-patient rare variant risk score.  Each patient was represented as a vector of de novo, 
transmitted, and copy number variant counts for all combinations of relevant variant functional 
classes (LGD, Dmis, DEL, DUP) and gene sets (HHE&NDD-risk, CHD-risk, HHE&pLI, HHE 
or pLI, other).  We used the association analysis described above to identify the gene groups 
most relevant to NDD and used the Fisher’s Exact Test enrichment values (odds ratio) as the 
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weights in our score.  Weights from the association analysis in specific CHD subtypes (Isolated, 
Complex, Unknown) were used where available.  Final weights can be found in Tables 2.6, 2.7, 
2.8.  For each patient, a rare variant risk score was calculated by taking the sum of the log2-
scaled product of the variants vector and the weights vector (𝑠𝑐𝑜𝑟𝑒 = ∑ 𝑙𝑜𝑔2𝑅𝑅𝑖, 𝑣,𝑔 ∗ 1𝑖,𝑣,𝑔
𝑛
𝑖  for 
each variant type v in {LGD, Dmis, DEL, DUP} and gene set g in {HHE&NDD-risk, CHD-risk, 
HHE&pLI, HHE or pLI, other}).  We generated per-patient risk scores within each variant class 
(de novo, transmitted, CNV) as well as a composite score combining information across the 
variant classes.  Given that transmitted variants were only available for the 2618 EUR cases, we 
limited subsequent analysis involving this composite rare variant risk score to these 2618 cases.   
 We next evaluated the utility of our score in discriminating between patients with and 
without the clinical outcome of interest (NDD).  We first compared the mean score values in 
NDD and non-NDD to assess the magnitude of difference.  We used a two-sided Wilcoxon 
Rank-Sum Test to test the null hypothesis that it is equally likely that a randomly selected score 
value from our NDD group will be greater/less than a randomly selected score from our non-
NDD group.  To identify optimal score thresholds for our rare variant risk score, we iterated over 
score values by percentile (0 to 100) and calculated the Matthews correlation coefficient (MCC = 
[TPxTN–FPxFN]/sqrt[(TP+FP)(TP+FN)(TN+FP)(TN+FN)]) to quantify the correlation between 
that particular score value threshold and NDD status while accounting for imbalanced class sizes 
(>Fig. 2.10).  We next used a 10-fold cross validation approach to evaluate our score’s predictive 
ability.  Patients were first randomly divided into 10 folds.  For each fold k, we split our dataset 
into testing (fold k) and training (remaining 9 folds) sets.  We then estimated weights using the 
cases in the training set and calculated risk scores for each patient in the held-out testing set.  To 
calculate per-fold area under precision-recall curve (AUPRC), we iterated over score values by 
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percentile (0 to 100) and calculated Precision (TP/(TP+FP)) and Recall (TP/(TP+FN)) for each 
score threshold.  We used R package DescTools (v.0.99.30) to estimate AUPRC.  We then 
calculated mean AUPRC across folds as our final risk score performance metric.  This analysis 
was repeated for each CHD subtype (Isolated, Complex, Unknown).    
 To calculate prevalence of NDD as a function of risk score percentile, we iterated over 
score values by percentile (0 to 100) and calculated the fraction of NDD patients with scores 
above the percentile cutoff (prevalence = # NDD patients / # total patients).  To calculate 
enrichment by quartile, we compared the number of NDD and non-NDD cases in each quartile 




Figure 29. Matthews Correlation Coefficient (MCC) for composite score thresholds, by 
percentile.  
(A) All cases. (B) Isolated cases. (C) Complex cases. (D) Unknown cases.  High risk score values have the strongest 


























































LGD 6 0.01 15 0.01 0.00 0.97 1 0.97 1 
Dmis 17 0.03 24 0.02 0.01 1.73 0.09 1.74 0.08 
HHE & 
pLI 
LGD 25 0.04 32 0.02 0.02 1.90 0.02 2.00 0.02 
Dmis 18 0.03 38 0.02 0.00 1.15 0.66 1.16 0.66 
HHE or 
pLI 
LGD 26 0.04 63 0.04 0.00 1.01 1 1.02 0.91 
Dmis 58 0.09 83 0.05 0.04 1.70 0.002 1.74 0.003 
Other 
Genes 
LGD 45 0.07 95 0.06 0.01 1.15 0.46 1.19 0.38 








LGD 14 0.03 8 0.01 0.03 5.36 0.0001 5.51 0.0001 




LGD 5 0.01 10 0.01 0.00 1.53 0.39 1.54 0.38 
Dmis 7 0.02 16 0.01 0.00 1.34 0.48 1.35 0.47 
HHE & 
pLI 
LGD 10 0.02 24 0.02 0.01 1.28 0.55 1.34 0.42 
Dmis 9 0.02 28 0.02 0.00 0.99 1 0.99 1 
HHE or 
pLI 
LGD 14 0.03 53 0.04 -0.01 0.81 0.57 0.82 0.56 
Dmis 33 0.08 72 0.06 0.02 1.41 0.11 1.46 0.10 
Other 
Genes 
LGD 31 0.08 67 0.05 0.02 1.42 0.13 1.45 0.11 


















LGD 1 0.00 5 0.02 -0.01 0.27 0.25 0.27 0.25 
Dmis 10 0.04 8 0.02 0.02 1.69 0.34 1.72 0.33 
HHE & 
pLI 
LGD 15 0.06 8 0.02 0.04 2.54 0.03 2.64 0.03 
Dmis 9 0.04 10 0.03 0.01 1.22 0.66 1.23 0.81 
HHE or 
pLI 
LGD 12 0.05 10 0.03 0.02 1.63 0.28 1.66 0.28 
Dmis 25 0.10 11 0.03 0.07 3.08 0.001 3.02 0.004 
Other 
Genes 
LGD 14 0.06 28 0.09 -0.03 0.68 0.28 0.71 0.41 
Dmis 14 0.06 27 0.08 -0.02 0.70 0.34 0.71 0.41 
N_NDD=number of NDD cases, N_non=number of non-NDD cases, DNV=de novo variant, Delta=difference in 
rates, RR=relative risk (Binomial Test), OR=Odds Ratio (Fisher’s Exact Test), HHE=high heart expression genes, 







































LGD 394 0.87 887 0.79 0.08 1.10 0.12 1.14 0.24 
Dmis 743 1.64 2016 1.80 -0.16 0.91 0.03 0.87 0.33 
Other 
Genes 
LGD 1482 3.26 3869 3.45 -0.18 0.95 0.07 0.88 0.58 







LGD 246 0.83 708 0.79 0.05 1.06 0.43 1.07 0.64 
Dmis 483 1.64 1626 1.80 -0.17 0.91 0.06 0.85 0.35 
Other 
Genes 
LGD 967 3.28 3102 3.44 -0.16 0.95 0.18 0.75 0.25 







LGD 148 0.93 179 0.81 0.12 1.15 0.22 1.21 0.40 
Dmis 260 1.64 390 1.76 -0.13 0.93 0.36 0.98 1 
Other 
Genes 
LGD 515 3.24 767 3.47 -0.23 0.93 0.23 1.28 0.66 
Dmis 740 4.65 991 4.48 0.17 1.04 0.45 1.18 0.82 
N_NDD=number of NDD cases, N_non=number of non-NDD cases, DNV=de novo variant, Delta=difference in 
rates, RR=relative risk (Binomial Test), OR=Odds Ratio (Fisher’s Exact Test), HHE=high heart expression genes, 






















































DEL 5 0.02 4 0.01 0.01 2.97 0.14 3.00 0.14 
DUP 1 0.00 1 0.00 0.00 2.37 0.50 2.38 0.51 
HHE & 
pLI 
DEL 3 0.01 3 0.00 0.01 2.37 0.37 2.39 0.37 
DUP 3 0.01 11 0.01 -0.01 0.65 0.77 0.64 0.77 
HHE or 
pLI 
DEL 4 0.01 10 0.01 0.00 0.95 1 0.95 1 
DUP 4 0.01 10 0.01 0.00 0.95 1 1.06 1 
Other 
Genes 
DEL 10 0.03 14 0.02 0.01 1.70 0.26 1.72 0.26 



















DEL 5 0.02 4 0.01 0.02 3.45 0.06 3.51 0.06 
DUP 1 0.00 1 0.00 0.00 2.76 0.46 2.77 0.46 
HHE & 
pLI 
DEL 1 0.00 2 0.00 0.00 1.38 1 1.38 1 
DUP 2 0.01 9 0.01 -0.01 0.61 0.74 0.61 0.74 
HHE or 
pLI 
DEL 3 0.01 9 0.01 0.00 0.92 1 0.92 1 
DUP 3 0.01 9 0.01 0.00 0.92 1 1.04 1 
Other 
Genes 
DEL 7 0.03 13 0.02 0.01 1.49 0.45 1.50 0.44 









DEL 4 0.04 2 0.01 0.03 2.95 0.23 3.02 0.22 




DEL 0 0.00 0 0.00 0.00 NA 0 0 1 
DUP 0 0.00 0 0.00 0.00 NA 0 0 1 
HHE & 
pLI 
DEL 2 0.02 1 0.01 0.01 2.95 0.57 2.98 0.57 
DUP 1 0.01 2 0.01 0.00 0.74 1 0.73 1 
HHE or 
pLI 
DEL 1 0.01 1 0.01 0.00 1.47 1 1.48 1 
DUP 1 0.01 1 0.01 0.00 1.47 1 1.48 1 
Other 
Genes 
DEL 3 0.03 1 0.01 0.02 4.42 0.31 4.50 0.31 
DUP 1 0.01 3 0.02 -0.01 0.49 0.65 0.49 0.65 
N_NDD=number of NDD cases, N_non=number of non-NDD cases, var=variant, DEL=deletion, 
DUP=duplication, Delta=difference in rates, RR=relative risk (Binomial Test), OR=Odds Ratio (Fisher’s Exact 
Test), HHE=high heart expression genes, pLI=constrained genes, NDDrisk=known NDD risk genes, Other 








 In this dissertation, I have discussed the contribution of mosaicism and other types of 
variation to the genetic architecture of congenital heart disease.  In the first chapter, I presented 
the development of a novel computational method for detecting mosaic single-nucleotide 
variants in exome-sequencing data, EM-mosaic.  Recent publications have reported discordant 
validation rates and mosaic fraction/rate estimates due to differences in sequencing depth, variant 
calling, and mosaic detection approach.  Further, distinguishing mosaic from germline 
heterozygous mutations remains a challenge for current methods.  We addressed these gaps by 
developing an approach that combines heuristic variant filters, error modeling, and data-driven 
parameter estimation.  EM-mosaic achieved a 90% validation rate, among the highest in recent 
publications.  Simulation experiments demonstrated that our estimated prior mosaic fraction and 
posterior-odds based false discovery rate (FDR) estimate were consistent with the truth.  We 
found that 1% of CHD patients carries a mosaic likely contributing to their heart malformation 
and that roughly 1 in 8 individuals carries a mosaic event detectable in blood exome sequencing 
data.  Analysis of subjects with matched blood and heart tissue demonstrated that mutations in 
blood with relatively high allele fraction were more likely to also be found in the heart, 
supporting the notion of allele fraction as a proxy of cellular percentage and that mutations 
occurring earlier in development are more likely to be found across multiple tissues.  In the 
second chapter, to disentangle the biological mechanisms governing differences in genetic 
etiology across CHD complexities (Isolated, Complex, Unknown), I presented a statistical 
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approach to characterizing the association between genetic variation and clinical outcomes in 
CHD patients.  I found that damaging de novo variants are enriched in CHD patients with 
neurodevelopmental disorders (NDD) or with ventricular dysfunction phenotypes and that 
variants in high heart expression (HHE) genes, known NDD-risk genes, and constrained genes 
are most strongly associated. I then showed that pleiotropic de novo variants in HHE&NDD-risk 
genes and HHE&constrained genes contribute a disproportionately large fraction of the risk of 
acquiring comorbid neurodevelopmental disorder or ventricular dysfunction, respectively.  
Finally, using the association analysis results, I developed a proof-of-concept rare variant risk 
score to predict NDD in CHD patients on the basis of their genetic profile (detected de novo, rare 
inherited, and copy number variants) and the relative contributions of these variants across a 
variety of gene sets.  I show that this risk score can stratify patients in our CHD cohort in a 
clinically meaningful way and identify patients at increased risk of NDD. 
 Future directions for this work including expanding EM-mosaic to detect post-zygotic 
small insertions/deletion (indels) and developing a method of in silico variant validation at scale.  
Modeling indels is challenging since indel calling in general is less refined than SNV calling and 
many additional factors influence their deviation in allele fraction from expectation under 
germline conditions.  These factors include the type of event (insertion vs deletion), the size of 
the event, and the local sequence content (particularly GC%), all of which would need to be 
considered in, for example, a regression-based approach.  Currently, in silico variant validation 
remains a bottleneck for large-scale genetic studies.  In this work, we manually reviewed variant 
read pileup screenshots generated in IGV, which would be intractable for larger datasets 
containing an order of magnitude more variants.  Automated orthogonal validation approaches 
present an attractive alternative to manual review. DeepVariant {Poplin 2018}, for example, is 
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the current state-of-the-art for germline variant quality control.  However, extending its 
framework to mosaic variant validation would require training data that does not currently exist.  
However, it would be feasible to develop a synthetic training dataset by, for example, using 
transmitted germline variants with subsampled alternate allele read depth as “positives” and 
using mendelian error events with comparable variant allele fractions as “negatives”.   
As study cohorts increase in size and our ability to detect different classes of variants 
improve, we will soon be able to accurately determine the association between the full spectrum 
of genetic variation and clinical phenotypes of interest.  With improved measures and further 
development, the genetic risk score and other methods discussed here have the potential to 
provide clinically actionable information and to improve current disease diagnosis and 
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